Introduction {#s1}
============

The assembly and disassembly of specific protein complexes underlies many important signaling pathways in the cell. The HORMA domain ([@bib2]) is a conserved, structurally unique signaling module that forms complexes through a characteristic 'safety-belt' interaction in which the C-terminus of the domain wraps entirely around a short region of a binding partner ([@bib36]; [@bib62]; [@bib19]; [@bib30]). HORMA domain protein complexes participate in multiple cellular signaling pathways, including meiotic recombination control, DNA repair, and the spindle assembly checkpoint (SAC). While the regulated assembly of HORMA domain protein complexes has been extensively characterized, the mechanisms underlying their disassembly, which requires significant conformational changes to disrupt the extremely stable safety-belt interaction, are largely unknown.

In meiosis, homologous chromosomes must recognize one another and recombine, forming physical links called crossovers (COs) that enable their bi-orientation and segregation in meiosis I ([@bib91]). CO formation is promoted and regulated by a conserved family of HORMA domain proteins termed HORMADs. Early in meiotic prophase, HORMADs localize to chromosomes along their entire lengths, where they promote the introduction of DNA double-strand breaks and bias the repair of those breaks toward the homologous chromosome ([@bib66]). In both yeast and mammals, excess recombination is limited by a feedback mechanism that removes or redistributes HORMADs along the chromosome after sufficient COs have formed. The removal of HORMADs depends on a conserved AAA+ family ATPase, Pch2/TRIP13, without which the frequency and spatial distribution of COs is disrupted ([@bib53]; [@bib5]; [@bib24]; [@bib85]; [@bib50]; [@bib8]). We have previously shown that the HORMADs assemble into higher-order oligomers through head-to-tail safety-belt interactions, and that these interactions are critical for their meiotic functions ([@bib30]). As a predominant family of AAA+ ATPases function to disaggregate or disassemble protein complexes ([@bib13]; [@bib54]), it has been proposed that Pch2/TRIP13 mediates HORMAD removal from chromosomes through specific recognition and disassembly of chromosome-associated HORMAD complexes ([@bib8]).

Recently, mammalian TRIP13 has been shown to regulate the SAC, which monitors kinetochore-microtubule attachment in both mitosis and meiosis ([@bib45]). In this pathway, unattached kinetochores generate an inhibitor of the anaphase promoting complex/cyclosome (APC/C) called the mitotic checkpoint complex (MCC), which is composed of the MAD2, CDC20, BUBR1, and BUB3 proteins ([@bib20]; [@bib15]; [@bib67]). MAD2 is a relative of the meiotic HORMADs, and exists in one of two conformers: an inactive 'open' state (O-MAD2), and an active 'closed' state (C-MAD2) ([Figure 8---figure supplement 1A](#fig8s1){ref-type="fig"}) that binds CDC20 through a safety-belt interaction to form the core of the MCC ([@bib62]; [@bib37]; [@bib57]; [@bib7]). After all kinetochores become properly attached to microtubules, new MCC assembly is halted and the SAC is inactivated. Timely SAC inactivation requires two factors, TRIP13 ([@bib81]) and the HORMA domain protein p31(comet) ([@bib17]; [@bib86]; [@bib18]; [@bib78]; [@bib84]; [@bib38]), which recent evidence suggests may act together to directly disassemble the MCC. p31(comet) specifically recognizes and binds C-MAD2, and the p31(comet)-MAD2 interface overlaps MAD2\'s interface with BUBR1 in the intact MCC ([@bib86]; [@bib87]; [@bib72]; [@bib7]), suggesting that p31(comet) may compete with BUBR1 for MAD2 binding. Further, the combined activities of p31(comet) and TRIP13 can cause the dissociation of MAD2 from immunoprecipitated CDC20 or BUBR1 complexes in vitro ([@bib69]; [@bib14]).

Intriguingly, human *TRIP13* has also been identified as an oncogene: *TRIP13* is overexpressed in a number of human cancers ([@bib34]; [@bib77]; [@bib4]; [@bib81]), and can promote proliferation and invasion when overexpressed in human cell lines ([@bib4]). The source of *TRIP13*\'s oncogenic activity is unknown, but may stem from effects on chromosome structure and DNA repair pathways (as its meiotic functions would suggest), or may instead arise from aberrant regulation of the SAC.

Pch2/TRIP13 is thus directly implicated in the regulation of HORMA domain-mediated signaling in two separate pathways, meiotic recombination and the SAC. The mechanistic basis for this regulation, however, remains unknown. Here, we show that Pch2/TRIP13 comprises a new family of AAA+ ATPase protein remodelers, with a substrate-recognition domain similar to the NSF/p97/PEX1 remodeler family and a physical mechanism closely related to the bacterial ClpX unfoldase. We show that TRIP13 converts closed, active MAD2 to its inactive open conformer, and that p31(comet) functions as an adapter to recognize closed MAD2 and deliver it to TRIP13. Thus, TRIP13 regulates the SAC through MAD2 conformational conversion and safety belt disengagement, and a similar mechanism for HORMAD complex disassembly likely underlies the enzyme\'s regulatory functions in meiosis.

Results {#s2}
=======

Structure of *Caenorhabditis elegans* PCH-2 {#s2-1}
-------------------------------------------

Pch2/TRIP13 proteins are members of the functionally diverse AAA+ ATPase family ([@bib13]; [@bib83]). These proteins share a common architecture, with a family-specific N-terminal domain (NTD) responsible for localization or substrate recognition, and one or two AAA+ ATPase modules that typically assemble into a hexameric ring. AAA+ ATPases are extremely diverse and include DNA and RNA helicases, DNA replication initiators, and a large family termed the 'classic remodelers,' which disaggregate or unfold proteins; these include the SNARE complex disassembly factor NSF, the ubiquitin-directed disaggregase p97/Cdc48, and the ATPase component of the eukaryotic proteasome ([@bib13]).

Sequence comparisons of the Pch2/TRIP13 AAA+ ATPase module fail to clearly classify it within any well-characterized AAA+ family ([Figure 1A](#fig1){ref-type="fig"}). Moreover, sequence comparisons of the Pch2/TRIP13 NTD fail to identify homology to any known proteins. Therefore, we took a structural approach to determine the relationship of Pch2/TRIP13 to other AAA+ ATPases. We overexpressed and purified *Mus musculus* TRIP13 and its *C. elegans* ortholog PCH-2, and found that while TRIP13 adopts a range of oligomeric states from monomer to hexamer, PCH-2 forms a stable hexamer both with and without added nucleotides ([Figure 1C,D](#fig1){ref-type="fig"}). We next performed negative-stain electron microscopy (EM) on PCH-2; low-resolution class averages reveal a distinctly asymmetric hexamer in the absence of nucleotides, which becomes more symmetric and compact when ATP is added ([Figure 1E](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). We attempted crystallization both in the presence and absence of nucleotides, and successfully determined the crystal structure of PCH-2 without added nucleotide to a resolution of 2.3 Å. The structure reveals an elongated hexamer with an approximate 'dimer of trimers' symmetry and an overall shape similar to our EM class averages of this state ([Figure 2A](#fig2){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"}).10.7554/eLife.07367.003Figure 1.PCH-2/TRIP13 is a distinct class of hexmeric AAA+ ATPase.(**A**) Phylogenetic tree of selected AAA+ ATPases, colored by clade ([@bib13]). (**B**) Conserved AAA+ sequence motifs in Pch2/TRIP13, the 'classic remodelers', and *E. coli* ClpX. Pch2/TRIP13 and ClpX lack the first of two conserved arginine residues in the Arg finger region (yellow), and possess a Sensor 2 arginine (R385, red), which the classic remodelers lack. (**C**) Size-exclusion chromatography coupled to multi-angle light scattering (SEC-MALS) analysis of *C. elegans* PCH-2 in the absence of nucleotides. Hexamer molecular weight = 288.1 kDa; measured molecular weight = 252 kDa (red line). (**D**) SEC-MALS analysis of *M. musculus* TRIP13 in the absence of nucleotides. The wild-type protein (black) adopts a mixture of oligomeric states from monomer to hexamer, consistent with findings from *S. cerevisiae* Pch2 ([@bib8]). The proportion of higher-molecular weight oligomers increases upon the addition of ATP or non-hydrolyzable analogs (not shown). The ATP hydrolysis-defective TRIP13^E253Q^ mutant (gray, molecular weight measurements red) is predominantly hexameric both in the presence (shown) and absence of ATP. Molecular weight measurements by SEC-MALS (red) are shown for TRIP13^E253Q^; WT measurements (not shown) are consistent. (**E**) Selected negative-stain EM class averages of *C. elegans* PCH-2 without added nucleotides (Apo) or with added ATP. For example raw images, see [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.07367.003](10.7554/eLife.07367.003)10.7554/eLife.07367.004Figure 1---figure supplement 1.Negative-stain electron microscopy (EM) of *C. elegans* PCH-2.(**A**) Example negative-stain EM image of *C. elegans* PCH-2 without added nucleotide (Apo), and selected class averages from XMIPP clustering 2D alignment (from 32 classes, 5916 total particles). (**B**) Example negative-stain EM image of PCH-2 in the presence of 1 mM ATP, and selected class averages (from 16 classes, 4297 total particles). PCH-2 hexamers adopt a more compact and sixfold symmetric conformation after ATP addition. Because of the strong bias toward top-down views of the hexamer, 3D reconstructions were not attempted for either state.**DOI:** [http://dx.doi.org/10.7554/eLife.07367.004](10.7554/eLife.07367.004)10.7554/eLife.07367.005Figure 2.Structure of *C. elegans* PCH-2.(**A**) Overall structure of PCH-2. The hexamer shows a 'dimer of trimers' symmetry with chains A/B/C equivalent to chains D/E/F. Chains A/D and C/F are bound to SO~4~^−^ in the ATPase active site, and chains B/E are bound to ADP (space-fill representation). For data collection and refinement statistics, see [Table 1](#tbl1){ref-type="table"}. (**B**) Structural comparison of the PCH-2 NTD (residues 1--99) with the NSF N-C subdomain (residues 92--189; \[[@bib41]\]); Cα r.m.s.d. 1.94 Å over 55 residues. (**C**) Schematic of Pch2/TRIP13 domain structure vs NSF/p97. Pch2/TRIP13 shares these proteins\' N-C subdomain (blue) and one of their tandem AAA+ ATPase regions (green/red). (**D**) Close-up view of PCH-2 chain B, with domains colored as in (**C**), showing its packing against subunits A and C. (**E**) Close-up of ADP bound to PCH-2 chain B, with AAA+ motifs shown as sticks. For close-up views of all six active sites, see [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}. (**F**) Stereo view of refined 2*F*~*o*~ − *F*~*c*~ electron density at 2.3 Å resolution, contoured at 1.0 σ, for the bound ADP and surrounding residues in PCH-2 chain B. View is equivalent to (**E**); the small AAA domain has been removed for clarity.**DOI:** [http://dx.doi.org/10.7554/eLife.07367.005](10.7554/eLife.07367.005)10.7554/eLife.07367.006Figure 2---figure supplement 1.X-ray crystallographic analysis of *C. elegans* PCH-2.(**A**) Mean diffraction intensity divided by standard deviation (I/σ) (left axis, dotted lines) and the half--set correlation coefficient (CC~1/2~) (right axis, solid lines) for PCH-2 native diffraction data (see [Table 1](#tbl1){ref-type="table"}) along the three principal axes a\* (red), b\* (yellow), and c\* (blue). Resolution cutoffs corresponding to an I/σ of 1.0 and a CC~1/2~ of 0.5 for c\* (3.2 Å) and a\*/b\* (2.3 Å) are shown as dashed lines. (**B**) Simulated-annealing *F*~*o*~ − *F*~*c*~ electron density map, contoured at 3.0 σ, calculated from a model missing all bound nucleotides and SO~4~^−^ ions. Views roughly equivalent to [Figure 2E](#fig2){ref-type="fig"} are shown for each chain in the PCH-2 hexamer.**DOI:** [http://dx.doi.org/10.7554/eLife.07367.006](10.7554/eLife.07367.006)10.7554/eLife.07367.007Table 1.Data collection and refinement statistics**DOI:** [http://dx.doi.org/10.7554/eLife.07367.007](10.7554/eLife.07367.007)PCH-2 SeMetPCH-2 nativeData collection Synchrotron/BeamlineAPS 24ID-ESSRL 12-2 Resolution (Å)3.232.3 Wavelength (Å)0.979210.9795 Space groupC222~1~C222~1~ Unit cell dimensions (a, b, c) Å126.1, 239.5, 198.2126.7 241.0 197.9 Unit cell angles (α, β, γ) °90, 90, 9090, 90, 90 *I*/σ (last shell)9.3 (1.0)17.9 (0.8) [\*](#tblfn1){ref-type="table-fn"} *R*~sym~ (last shell)0.198 (2.166)0.098 (3.143) [†](#tblfn2){ref-type="table-fn"} *R*~meas~ (last shell)0.213 (2.326)0.102 (3.297) [‡](#tblfn3){ref-type="table-fn"} Isotropic CC~1/2~, last shell0.5920.275[§](#tblfn4){ref-type="table-fn"} Directional CC~1/2~, last shell (Å)  a\*--0.498 (2.3 Å)  b\*--0.532 (2.3 Å)  c\*--0.608 (3.2 Å) Completeness (last shell) %99.9 (99.9)99.5 (90.8) Number of reflections33,4621,808,343  *unique*4410134,133 Multiplicity (last shell)7.5 (7.6)13.5 (10.6) Number of sites68--[§](#tblfn4){ref-type="table-fn"} Anisotropic scaling B-factors (Å^2^)  a\*--−8.09  b\*--−8.02  c\*--16.11 isotropic B-factor correction--−19.65Refinement Resolution range (Å)--40 - 2.3 No. of reflections--96,084  *working*--91,200  *free*--4884 [\#](#tblfn5){ref-type="table-fn"} *R*~work~ (%)--22.97 [\#](#tblfn5){ref-type="table-fn"} *R*~free~ (%)--26.42Structure/Stereochemistry Number of atoms--18,017  *ligands* (*ADP, SO*~*4*~)--89  *solvent*--55 r.m.s.d. bond lengths (Å)--0.004 r.m.s.d. bond angles (°)--0.730 [¶](#tblfn6){ref-type="table-fn"} PDB ID--4XGU[^1][^2][^3][^4][^5][^6]

While the PCH-2 NTD (residues 1--99 of 424) lacks detectable sequence homology to other proteins, the structure of this domain shows a clear relationship to the N-terminal substrate recognition domains of a AAA+ 'classic remodeler' sub-family that includes NSF, p97, and PEX1. These proteins possess two-part NTDs with tightly associated N-N and N-C subdomains ([@bib41]; [@bib88]). A hydrophobic cleft between the two subdomains binds either directly to substrates, or alternatively to 'adapter' proteins that aid localization and specific substrate recognition ([@bib31]). In PCH-2, the NTD contains a single folded domain similar to the NSF/p97/PEX1 N-C subdomain ([Figure 2B](#fig2){ref-type="fig"}), and as such does not share these proteins\' substrate-binding hydrophobic cleft. Nonetheless, the similarity in NTD structure indicates a hitherto unappreciated evolutionary link between Pch2/TRIP13 and the NSF/p97/PEX1 remodeler family ([Figure 2C](#fig2){ref-type="fig"}), and strongly suggests that the PCH-2 NTD is involved in substrate recognition, either directly or indirectly through one or more adapter proteins.

PCH-2\'s single AAA+ ATPase module is composed of two domains, termed the large and small AAA domains. Structural comparisons using the DALI server ([@bib21]) indicate that the ATP-binding large AAA domain of PCH-2 (residues 100--323) is most structurally similar to the 'classic remodelers,' including NSF/p97/PEX1, Vps4, Katanin p60, and the proteasome ATPase subunits (2.7--3.4 Å r.m.s.d. comparing 150--170 Cα atoms). The domain also shows strong similarity to other AAA+ ATPase families including the 'HCLR' clade that includes ClpX, the unfoldase component of the bacterial ClpXP protease (3.2--3.3 Å r.m.s.d. comparing ∼150 Cα atoms) ([@bib16]; [@bib54]). The small AAA domain (residues 324--424) is most similar to 'classic remodeler' family members (1.5--2.0 Å r.m.s.d. comparing 60--70 Cα atoms).

As in other AAA+ ATPases, the PCH-2 hexamer assembles through interactions between each subunit\'s large AAA domain and the small AAA domain of a neighboring subunit, with the ATP-binding sites situated near the subunit interfaces ([Figure 2A,D](#fig2){ref-type="fig"}). Although no nucleotides were added during purification or crystallization of PCH-2, we observed that two subunits in the hexamer (chains B and E) are bound to ADP ([Figure 2A,E](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}), enabling a close analysis of PCH-2 active site structure. PCH-2 possesses the characteristic Walker A, Walker B, Sensor-1, and 'arginine finger' motifs in the large AAA domain that cooperate to bind nucleotide ([Figures 1B, 2E](#fig1 fig2){ref-type="fig"}) ([@bib83]). In many AAA+ ATPases, nucleotide binding is sensed by an additional 'Sensor-2' motif, typically an arginine residue, reaching from the small AAA domain into the active site. This motif is involved in nucleotide binding, hydrolysis, and nucleotide-dependent inter-domain conformational changes in various AAA+ ATPases ([@bib47]). Curiously, the 'classic remodelers' family, including NSF/p97/PEX1, uniformly lacks the Sensor-2 motif and also possesses a second arginine adjacent to the arginine finger ([Figure 1B](#fig1){ref-type="fig"}). These differences indicate that this family\'s mechanism for ATP-driven conformational changes may have diverged somewhat from other AAA+ ATPases ([@bib47]; [@bib13]). Pch2/TRIP13 proteins, in contrast, possesses only a single arginine finger (R312 in *C. elegans* PCH-2), and our PCH-2 structure shows that a conserved arginine (R385) is properly positioned to act as a Sensor-2 motif ([Figures 1B, 2E](#fig1 fig2){ref-type="fig"}). This finding suggests that despite sharing a common NTD with a family of 'classic remodelers', the detailed mechanism for nucleotide-dependent conformational changes in Pch2/TRIP13 may more closely resemble other AAA+ families.

Nucleotide-driven conformational changes in the PCH-2 hexamer {#s2-2}
-------------------------------------------------------------

The distinctly asymmetric hexamer architecture of PCH-2 provides clues to conformational changes that likely occur during ATP binding, hydrolysis, and release. Within the hexamer, four PCH-2 subunits adopt a 'closed' conformation equivalent to that observed in most AAA+ 'classic remodeler' structures, with the large and small AAA domains tightly associated around the ATP-binding site. Two of these subunits (chains B and E) are bound to ADP in our structure, while the other two (chains A and D) contain a SO~4~^−^ ion from the crystallization buffer. Asymmetry in the PCH-2 hexamer arises from large conformational differences in the remaining two subunits (chains C and F, also bound to SO~4~^−^), situated on opposite ends of the extended hexamer. Compared to the four closed subunits, these chains adopt an 'open' conformation, in which the small AAA domain is rotated ∼70° away from the large AAA domain ([Figure 3A--B](#fig3){ref-type="fig"}).10.7554/eLife.07367.008Figure 3.Conformational changes within the PCH-2 hexamer.(**A**) Structural basis for nucleotide binding-dependent conformational changes. All six subunits (A/D dark blue, B/E light blue, C/F green) are overlaid based on their large AAA domains, and their small AAA domains are represented by a single α-helix, residues 323--342. (**B**) Relative orientation of large and small AAA domains in different subunit types. Bound ADP and SO~4~^−^ ions are shown as sticks. While the small AAA domain position varies widely between subunits, all six subunit--subunit interfaces are equivalent, forming six rigid-body units within the hexamer (see [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). (**C**) 'Closed' (blue) and 'open' (green) ClpX monomers in the nucleotide-free ClpX hexamer (PDB ID 3HTE; \[[@bib16]\]). Later work showed that the 'closed' conformation is compatible with nucleotide binding ([@bib64]). (**D**) Top view of the asymmetric PCH-2 hexamer, with subunits colored as in (**A**) and (**B**), and pore loops (residues 217--226) colored magenta. (**E**) Pore-side view of PCH-2 D/E/F chains (A/B/C chains removed), showing the axial staggering of these subunits\' pore loops. (**F**) Top view of the nucleotide-free ClpX hexamer ([@bib16]), with 'closed' and 'open' subunits colored as in PCH-2 and pore loops (residues 145--153) colored magenta. (**G**) Pore-side view of ClpX D/E/F chains (A/B/C removed), colored as in (**F**). (**H**) Sequence alignment of pore loop region in PCH-2 orthologs, and equivalent region of human p97 and NSF, and *E. coli* ClpX. Magenta box: PCH-2 pore loop; Yellow boxes: NSF 'YVG' and ClpX 'GYVG' motifs. (**I**) Schematic model for ATP-driven conformational changes in PCH-2, with pore-side view equivalent to panel **F**. As the left-most subunit binds ATP (blue; represented by the closed 'ATP'-like state in chain D), hydrolyzes ATP to ADP (light blue; represented by PCH-2 chain E), then releases hydrolyzed ADP (green; represented by PCH-2 chain F), its pore loop (magenta) undergoes axial motions that drive substrate remodeling.**DOI:** [http://dx.doi.org/10.7554/eLife.07367.008](10.7554/eLife.07367.008)10.7554/eLife.07367.009Figure 3---figure supplement 1.The asymmetric PCH-2 hexamer is composed of equivalent rigid-body groups.(**A**) Overlaid large AAA domains of the six protein chains in the PCH-2 hexamer, as in [Figure 3A](#fig3){ref-type="fig"}, with associated small AAA+ domains from each neighboring subunit. While the small AAA domains of each subunit show significant conformational differences, the interface between each large AAA domain and the neighboring small AAA domain remains fixed. (**B**) Views as in panel (**A**) of each subunit type. Outlines in yellow, pink, and purple illustrate rigid-body rotation units within the hexamer, with NTDs removed for clarity (see below). Each rigid body is proposed to rotate as a unit in response to the nucleotide-binding state of its ATPase active site. (**C**) *Left:* top view of the PCH-2 hexamer (NTDs omitted for clarity), colored by protein chain as in [Figure 3](#fig3){ref-type="fig"}. *Center:* PCH-2 hexamer colored as in (**A**), with outlines in yellow, pink, and purple as in (**B**) highlighting rigid-body rotation units in the hexamer. *Right:* PCH-2 with rigid-body units colored as in (**B**). Each rigid-body unit comprises the large AAA domain from one chain (e.g., chain B) and the small AAA domain from its neighbor (e.g., chain A). Cyan ovals indicate the locations of ATPase active sites, positioned between each rigid-body unit.**DOI:** [http://dx.doi.org/10.7554/eLife.07367.009](10.7554/eLife.07367.009)

The dramatic conformational differences between subunits, and the resulting overall hexamer architecture of PCH-2, are distinct from most existing structures of AAA+ 'classic remodelers', which are typically either symmetric or display a subtle helical pitch resulting in a 'lock-washer' conformation, and usually lack the significant rotations between large and small AAA domains seen in PCH-2 ([@bib11]; [@bib32]; [@bib90]). Instead, the PCH-2 structure closely resembles several prior structures of the ClpX unfoldase, which contain four 'closed' and two 'open' subunits arranged in the same pattern as in PCH-2 ([Figure 3C,F,G](#fig3){ref-type="fig"}) ([@bib16]; [@bib64]). This conformation was observed both in the absence of nucleotides ([@bib16]) and in the presence of a non-hydrolyzable ATP analog (ATP-γ-S), which was found to bind the four 'closed' subunits but not the two 'open' subunits ([@bib64]). Detailed biochemical analysis of the ClpX mechanism has demonstrated that sequential ATP binding, hydrolysis, and release drive cyclical open → closed → open conformational changes within each subunit ([@bib16]; [@bib64]). These motions in turn drive axial movement of loops lining the hexamer pore (pore loops), which contain aromatic residues that directly engage substrate proteins during unfolding ([@bib60]; [@bib23]). Despite a potentially diverged mechanism for ATP-powered conformational changes, the classic remodelers possess functionally equivalent pore loops ([@bib89]). Within each half-hexamer of PCH-2 (chains A/B/C and D/E/F), the pore loops (residues 217--226; [Figure 3H](#fig3){ref-type="fig"}) are axially staggered to create a 'spiral staircase' of likely substrate-engaging groups. We interpret these pore loop positions as representing structural intermediates adopted during ATP binding, hydrolysis, and release within each PCH-2 subunit that drive substrate remodeling ([Figure 3I](#fig3){ref-type="fig"}).

ATP binding and hydrolysis in PCH-2 and *M. musculus* TRIP13 {#s2-3}
------------------------------------------------------------

To test the physical mechanism of Pch2/TRIP13 and the roles of active-site and pore-loop residues, we measured nucleotide binding and hydrolysis by PCH-2 and its *M. musculus* ortholog TRIP13. As in other AAA+ ATPases, a mutation in the Walker B motif of both PCH-2 and TRIP13 (E253Q in both enzymes) retains high-affinity nucleotide binding, while PCH-2 Walker A and Sensor-1 mutants do not bind nucleotide ([Figure 4A,B](#fig4){ref-type="fig"}). We found that TRIP13^E253Q^ also forms stable hexamers, in contrast to the predominantly monomeric wild-type enzyme ([Figure 1D](#fig1){ref-type="fig"}). Mutation of PCH-2 R385 also results in the loss of nucleotide binding, illustrating that this residue is likely to be functionally analogous to the Sensor-2 motifs in other AAA+ ATPases.10.7554/eLife.07367.010Figure 4.Nucleotide binding and hydrolysis by PCH-2 and TRIP13.(**A**) Binding of PCH-2 active-site mutants to BODIPY-FL ATP. (**B**) Binding of *M. musculus* TRIP13^E253Q^ to BODIPY-FL ATP. (**C**) Basal ATP hydrolysis rates of wild-type and mutant *C. elegans* PCH-2 at pH 8.5 (optimal for ATPase activity; ATPase stimulation assays ([Figure 6](#fig6){ref-type="fig"}) were performed at pH 7.5, where basal activity is lower but stimulation is more robust). E253Q: Walker B ATPase mutant; W221A/F222A: pore loop mutants; WT ΔNTD: residues 100--424. (**D**) Basal ATP hydrolysis rates of wild-type and mutant *M. musculus* TRIP13 at pH 8.5. Residue numbering for mutants is identical to *C. elegans* PCH-2. (**E**) *K*~*m*~/*k*~*cat*~ values (reported as ATP min^−1^ per hexameric enzyme) for wild-type and mutant PCH-2 and TRIP13. For PCH-2^T186A^, PCH-2^N300A^, and PCH-2^R385A^, rates were measured at a single ATP concentration of 2 mM, so *K*~*m*~ was not determined (N/D). For PCH-2^E253Q^ and TRIP13^E253Q^, very low ATPase activity precluded a reliable *K*~*m*~ determination (N/A).**DOI:** [http://dx.doi.org/10.7554/eLife.07367.010](10.7554/eLife.07367.010)

We used an enzyme-coupled assay to measure ATP hydrolysis by PCH-2 and TRIP13. Both enzymes showed modest but reproducible ATPase activity, and mutation of conserved active site residues resulted in the complete loss of activity ([Figure 4C--E](#fig4){ref-type="fig"}). We next tested the importance of the enzymes\' pore loops, which in other AAA+ ATPases are necessary to properly couple ATP hydrolysis to substrate engagement ([@bib60]). We generated alanine mutants of PCH-2 W221 and F222, which align with the ClpX/NSF 'YVG'/'GYVG' motifs ([Figure 3H](#fig3){ref-type="fig"}), and also created a 'pore loop AG' mutant (PCH-2^AG^) in which residues 218-227 were replaced by an Ala-Gly linker of equal length. These mutants all formed soluble hexamers as in wild-type PCH-2, but showed variable ATPase activity: while PCH-2^F222A^ showed a fivefold reduction in basal ATPase activity, PCH-2^W221A^ and PCH-2^AG^ showed a striking increase in activity, with the *k*~*cat*~ of PCH-2^W221A^ around threefold higher than that of the wild-type enzyme ([Figure 4C,E](#fig4){ref-type="fig"}). Similarly, *M. musculus* TRIP13^W221A^ had a more than twofold higher basal *k*~*cat*~ than wild-type TRIP13 ([Figure 4D,E](#fig4){ref-type="fig"}). The variable effect of pore loop mutations in PCH-2/TRIP13 suggests that this element may play a role in coupling ATP hydrolysis to substrate engagement.

p31(comet) functions as an adapter between MAD2 and TRIP13 {#s2-4}
----------------------------------------------------------

Timely SAC inactivation relies on both TRIP13 and p31(comet), and prior work has shown that the two proteins can together dissociate MAD2:CDC20 complexes in vitro ([@bib14]). As p31(comet) is known to bind both MAD2 ([@bib17]; [@bib87]) and TRIP13 ([@bib73]), we reasoned that the protein may act as an adapter. We mapped sequence conservation onto the structure of human p31(comet):MAD2 ([@bib87]), and identified a highly conserved surface on p31(comet) opposite its MAD2-binding interface ([Figure 5A](#fig5){ref-type="fig"}). To test whether this surface, which includes residues on the p31(comet) 'safety-belt' and a short loop bordering this motif, is responsible for TRIP13 interaction, we generated a series of mutations in *M. musculus* p31(comet). Several mutations to this conserved surface disrupted TRIP13 binding in a yeast two-hybrid assay, while retaining MAD2 binding ([Figure 5B](#fig5){ref-type="fig"}). Conversely, a previously-characterized mutant at the MAD2 interface ([@bib87]) disrupted MAD2 binding but did not affect the interaction with TRIP13 ([Figure 5B,D](#fig5){ref-type="fig"}). To test whether p31(comet) is able to simultaneously interact with MAD2 and TRIP13, we performed a yeast three-hybrid assay. This assay showed an interaction between TRIP13 and MAD2 that depends on the presence of untagged p31(comet) ([Figure 5C](#fig5){ref-type="fig"}), showing that p31(comet) can indeed function as an adapter between MAD2 and TRIP13 ([Figure 5G](#fig5){ref-type="fig"}).10.7554/eLife.07367.011Figure 5.p31(comet) functions as an adapter between TRIP13 and MAD2.(**A**) Two views of the crystal structure of human p31(comet) (colored by conservation) bound to MAD2 (yellow) ([@bib87]). Residue numbers shown are of *M. musculus* p31(comet) (76% identity with *Homo sapiens* p31(comet); all noted residues are conserved). (**B**) Yeast two-hybrid assay for *M. musculus* p31(comet) binding to TRIP13 and MAD2. The p31(comet)-MAD2 interaction can also be detected using purified proteins (panel **D**). BD: Gal4 DNA-binding domain fusion; AD: Gal4 activation domain fusion. N/S: no selection; -HIS: selection for interaction between BD- and AD-fused proteins. (**C**) Yeast three-hybrid assay showing interaction of BD-TRIP13 and AD-MAD2 in the presence of untagged p31(comet). (**D**) Ni^2+^-pulldown assay using purified His~6~-tagged *M. musculus* p31(comet) pulling down untagged *M. musculus* MAD2. (**E**) Size exclusion chromatography traces and gels from *M. musculus* TRIP13^E253Q^ (yellow), p31(comet):C-MAD2^R133A^ (blue), and an equimolar mixture of TRIP13^E253Q^ + p31(comet):C-MAD2^R133A^ (green). Quantitation of Coomassie-stained bands in bottom gel (lanes 2 and 3) show an ∼6:1 molar ratio of TRIP13^E253Q^ to p31(comet):MAD2 (6 copies of TRIP13, 1.06 copies of p31(comet) and 0.74 copies of C-MAD2^R133A^). See [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} for full gels and analysis of different protein combinations including p31(comet) mutants, and [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"} for purification of p31(comet) and MAD2. (**F**) SEC-MALS analysis of TRIP13^E253Q^ (yellow) and TRIP13^E253Q^:p31(comet):C-MAD2^R133A^ (green). TRIP13^E253Q^ migrates as a single peak with measured molecular weight of 251 kDa, close to the calculated hexamer molecular weight of 290.2 kDa. Upon the addition of p31(comet) and C-MAD2^R133A^, the measured molecular weight shifts to 325 kDa. The shift of 74 kDa is close to the weight of a p31(comet):C-MAD2^R133A^ complex (54.7 kDa). Excess p31(comet):C-MAD2^R133A^ elutes after the complex with TRIP13. (**G**) Schematic illustrating p31(comet) functioning as an adapter between C-MAD2 (via blue surface) and TRIP13 (via red surface). See [Figure 8---figure supplement 1C](#fig8s1){ref-type="fig"} for the p31(comet) crystal structure colored equivalently.**DOI:** [http://dx.doi.org/10.7554/eLife.07367.011](10.7554/eLife.07367.011)10.7554/eLife.07367.012Figure 5---figure supplement 1.Interactions between *M. musculus* TRIP13, p31(comet), and MAD2.Size exclusion chromatography traces and gels from mixtures of separately purified *M. musculus* TRIP13^E253Q^, p31(comet), and C-MAD2^R133A^.**DOI:** [http://dx.doi.org/10.7554/eLife.07367.012](10.7554/eLife.07367.012)10.7554/eLife.07367.013Figure 5---figure supplement 2.Purification and characterization of *M. musculus* MAD2 and p31(comet).(**A**) Anion-exchange purification of *M. musculus* MAD2^R133A^. O-MAD2^R133A^ and C-MAD2^R133A^ peaks are noted. The MAD2 'loopless' mutant (residues 109--117 replaced by GSG (adopts monomeric open form) \[[@bib40]\]) eluted at the same salt concentration as the O-MAD2^R133A^ peak (not shown). (**B**) SDS-PAGE analysis of fractions from (**A**). (**C**) SEC-MALS analysis of *M. musculus* MAD2. Wild-type MAD2 (top, black) is predominantly dimeric, while O-MAD2^R133A^ (green), C-MAD2^R133A^ (blue), and 'loopless' MAD2 are predominantly monomeric. (**D**) SDS-PAGE analysis of final purified MAD2 WT, O-MAD2^R133A^, C-MAD2^R133A^, and 'loopless' MAD2.**DOI:** [http://dx.doi.org/10.7554/eLife.07367.013](10.7554/eLife.07367.013)

We next sought to reconstitute the TRIP13:p31(comet):MAD2 complex in vitro. We separately purified *M. musculus* TRIP13^E253Q^, which is catalytically inactive and forms more stable hexamers than wild-type TRIP13 ([Figure 1D](#fig1){ref-type="fig"}), wild-type p31(comet), and a monomeric variant of MAD2 (MAD2^R133A^) in which open (O-MAD2) and closed (C-MAD2) monomers can be separately purified ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}) ([@bib61]; [@bib37]; [@bib39]). We mixed TRIP13^E253Q^, p31(comet), and C-MAD2^R133A^ in the presence of ATP, and measured complex formation using size-exclusion chromatography. In agreement with prior studies ([@bib87]), p31(comet) and C-MAD2^R133A^ formed a stable heterodimeric complex. When this complex was pre-incubated with TRIP13^E253Q^, a small amount of both proteins was shifted into the TRIP13 hexamer peak ([Figure 5E](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Semi-quantitative analysis of Coomassie-stained gels, and light-scattering based molecular-weight measurements on this peak, revealed that for each TRIP13^E235Q^ hexamer, about 1 copy of p31(comet):C-MAD2^R133A^ was shifted into the TRIP13 peak ([Figure 5E,F](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). MAD2 did not shift in the absence of p31(comet), and only a very small amount of p31(comet) shifted in the absence of MAD2 ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). p31(comet) mutants that disrupt either MAD2 or TRIP13 binding also largely eliminated p31(comet):MAD2 co-migration with TRIP13^E253Q^ ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Taken together with our yeast two-hybrid results, these data suggest that a single p31(comet):MAD2 complex associates with a TRIP13 hexamer, first through transient TRIP13-p31(comet) binding (likely mediated by the TRIP13 NTD), then through direct interactions between TRIP13 and MAD2 (at the TRIP13 hexamer pore). We were unable to directly test the role of the TRIP13 pore loops in binding, however, as the TRIP13^W221A/E253Q^ double mutant did not form stable hexamers (data not shown).

PCH-2/TRIP13 ATPase activity is stimulated by p31(comet) + MAD2 {#s2-5}
---------------------------------------------------------------

We next examined whether PCH-2 or TRIP13 ATPase activity is stimulated by MAD2, p31(comet), or the p31(comet):MAD2 complex. While PCH-2 ATPase activity was mostly unaffected by the addition of either MAD-2 or the recently-identified p31(comet) ortholog CMT-1 ([@bib79]), it was modestly stimulated in the presence of both proteins ([Figure 6A](#fig6){ref-type="fig"}). A PCH-2 construct missing the NTD was not stimulated by the addition of MAD-2 + CMT-1, supporting the proposed role for this domain in substrate recognition ([Figure 6A](#fig6){ref-type="fig"}). The PCH-2^W221A^ pore-loop mutant was also not stimulated by MAD-2 + CMT-1, supporting the idea that this mutant uncouples ATP hydrolysis from productive substrate engagement ([Figure 6A](#fig6){ref-type="fig"}).10.7554/eLife.07367.014Figure 6.ATP hydrolysis in PCH-2/TRIP13 is stimulated by p31(comet) + MAD2.(**A**) Stimulation of *C. elegans* PCH-2 ATPase activity by CMT-1 (p31(comet)) and MAD-2. See [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} for purification of *C. elegans* CMT-1 and MAD-2. Cdc20: N-terminal MBP fusion of *C. elegans* FZY-1 residues 98-140. Substrates were in sixfold molar excess of PCH-2 hexamer. (**B**) Stimulation of *M. musculus* TRIP13 ATPase activity by p31(comet) and MAD2. WT: wild-type MAD2 dimer; 'open': O-MAD2^R133A^ monomer; 'closed': C-MAD2^R133A^ monomer; 'loopless': residues 109--117 replaced by GSG (adopts monomeric open form) ([@bib40]). CDC20: N-terminal MBP fusion of CDC20 residues 111--150, sufficient for MAD2 binding ([@bib35]). Substrates were in sixfold molar excess of TRIP13 hexamer. (**C**) Stimulation of TRIP13 ATPase activity in the presence of p31(comet) mutants. (**D**) Schematic illustrating requirements for TRIP13 stimulation. PCH-2/TRIP13 is stimulated by the combination of C-MAD2 and p31(comet) (scheme 1); mutation of either binding surface of p31(comet) (schemes 2 and 3) eliminates stimulation, as does replacement of C-MAD2 with O-MAD2 (scheme 4). p-values in (**A**) and (**C**) were calculated using an unpaired Student\'s T-test.**DOI:** [http://dx.doi.org/10.7554/eLife.07367.014](10.7554/eLife.07367.014)10.7554/eLife.07367.015Figure 6---figure supplement 1.Purification and characterization of *C. elegans* MAD-2 and CMT-1.(**A**) SEC-MALS analysis of *C. elegans* MAD-2 shows a mixture of monomer and dimer states. These were separately pooled for PCH-2 ATPase stimulation assays; while both pools stimulated PCH-2 in the presence of CMT-1, the dimer peak more strongly stimulated PCH-2 (not shown). (**B**) SDS-PAGE analysis of purified *C. elegans* MAD-2. (**C**) Size exclusion chromatography and SDS-PAGE analysis of *C. elegans* CMT-1, showing that the protein is monomeric (elution volume of size standards shown for comparison). (**D**) SDS-PAGE analysis of fractions from (**C**).**DOI:** [http://dx.doi.org/10.7554/eLife.07367.015](10.7554/eLife.07367.015)

*M. musculus* TRIP13 was strongly stimulated by the addition of MAD2 + p31(comet) ([Figure 6B](#fig6){ref-type="fig"}). Stimulation did not depend on the presence of CDC20, but was highly sensitive to MAD2 conformation: while C-MAD2^R133A^ stimulated TRIP13 equivalently to wild-type MAD2, O-MAD2^R133A^ showed minimal stimulation, and the locked-open 'loopless' MAD2 mutant ([@bib40]) showed no stimulation ([Figure 6B](#fig6){ref-type="fig"}). As with PCH-2, neither MAD2 nor p31(comet) alone had a stimulatory effect on TRIP13. Also consistent with PCH-2, the TRIP13^W221A^ pore-loop mutant showed a very high basal level of ATP hydrolysis, and was not further stimulated by MAD2 + p31(comet) ([Figure 6B](#fig6){ref-type="fig"}). Finally, we found that p31(comet) mutations that disrupt either MAD2 or TRIP13 binding also significantly reduce stimulation of TRIP13 by p31(comet) + MAD2 ([Figure 6C,D](#fig6){ref-type="fig"}).

TRIP13 catalyzes the conversion of closed MAD2 to the open conformer {#s2-6}
--------------------------------------------------------------------

The above results suggest a model in which p31(comet) recognizes C-MAD2 and delivers it to TRIP13 for remodeling. If TRIP13 functions by unfolding MAD2, or alternatively converting C-MAD2 to O-MAD2, a prolonged incubation with TRIP13 should eliminate the stimulatory effect of p31(comet) + MAD2. This is indeed the case: we found that the ability of p31(comet) + MAD2 to stimulate TRIP13 ATPase activity was almost eliminated after a 2-hr pre-incubation, in an ATP-dependent manner ([Figure 7A](#fig7){ref-type="fig"}, compare samples \#2, 3, and 4). Importantly, p31(comet) and MAD2 were in sixfold molar excess to TRIP13 hexamers in this assay, illustrating that each TRIP13 hexamer acted on multiple p31(comet):MAD2 complexes during the pre-incubation period. Addition of fresh MAD2 to the pre-incubated samples rescued TRIP13 stimulation ([Figure 7A](#fig7){ref-type="fig"}, sample \#5). We interpret these findings to indicate that TRIP13 is stimulated by the p31(comet):MAD2 complex but acts on MAD2 specifically, likely converting C-MAD2 into the non-stimulatory open state ([Figure 7B](#fig7){ref-type="fig"}).10.7554/eLife.07367.016Figure 7.TRIP13 converts C-MAD2 to O-MAD2.(**A**) Stimulation of TRIP13 ATPase activity by p31(comet ) + MAD2, before (samples 1--2) or after (samples 3--5) a 2-hr pre-incubation period. All proteins were at 4 μM (sixfold molar excess of substrate:TRIP13 hexamer). For sample 5, an additional 4 μM MAD2 was added after the pre-incubation period. (**B**) Schematic illustrating results from (**A**) in terms of complex formation and TRIP13 stimulation. (**C**) Anion-exchange elution profiles for O-MAD2 (green), C-MAD2 (gray), and the p31(comet):C-MAD2 complex (blue). (**D**) p31(comet) and MAD2 in anion-exchange fractions from the indicated pre-incubated reaction mixtures. p31(comet) and MAD2 were at 30 μM, and TRIP13 at 5 μM (hexamer concentration) except for starred sample (third from top), where TRIP13 was at 1.25 μM. The observed C-MAD2 to O-MAD2 conversion requires active TRIP13, ATP, and p31(comet). Neither TRIP13^E253Q^ nor TRIP13^W221A^ supported MAD2 conversion. At equilibrium, MAD2^R133A^ is predominantly in the C-MAD2 state ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}), further supporting that the observed C-MAD2 to O-MAD2 conversion is an active process. (**E**) Rate of TRIP13-mediated C-MAD2 to O-MAD2 conversion in limiting TRIP13. Reactions with 30 μM p31(comet) + MAD2^R133A^ (initially ∼10 μM O-MAD2 and ∼20 μM C-MAD2) were incubated at 37°C for 30 min with the indicated amounts of TRIP13, and separated by ion-exchange as in (**D**). SDS-PAGE band intensities were quantified, converted to \[O-MAD2\], and plotted. Linear regression fitting indicates a rate of 57.4 ± 6.7 MAD2 conversions in 30 min per TRIP13 hexamer, or ∼1.9 ± 0.2 min^−1^ (**F**) TRIP13-mediated MAD2 conversion in the presence of p31(comet) mutants. The high concentration of p31(comet) + MAD2 in this assay (30 μM) allowed single mutants to support limited MAD2 conversion, but mutant combinations effectively eliminated MAD2 conversion. PK: P230A/K231A; QF: Q86A/F193A. (**G**) ATPase activity of *M. musculus* TRIP13 at 37°C (all other ATPase assays were performed at 27°C).**DOI:** [http://dx.doi.org/10.7554/eLife.07367.016](10.7554/eLife.07367.016)10.7554/eLife.07367.017Figure 7---figure supplement 1.MAD2^R133A^ is predominantly in the C-MAD2 state at equilibrium.(**A**) Purified samples of O-MAD2^R133A^ (30 μM total concentration) were separated by anion-exchange chromatography as in [Figure 7C--D](#fig7){ref-type="fig"}, either as purified (0 hr) or after a 24 hr incubation at 37°C. Quantitation of SDS-PAGE bands in fractions 2--3 (O-MAD2) vs fractions 5--6 (C-MAD2) indicate that the sample is 13% C-MAD2 prior to incubation, and 87% C-MAD2 after incubation. (**B**) Purified samples of C-MAD2^R133A^ were analyzed as in (**A**). The sample is 64% C-MAD2 prior to incubation, and 85% C-MAD2 after incubation.**DOI:** [http://dx.doi.org/10.7554/eLife.07367.017](10.7554/eLife.07367.017)

To directly assay whether TRIP13 converts C-MAD2 to O-MAD2, we took advantage of the fact that in the dimerization-defective MAD2^R133A^ mutant, the open and closed conformers are separable by anion-exchange chromatography ([Figure 7C](#fig7){ref-type="fig"}, [Figure 5---figure supplement 2A](#fig5s2){ref-type="fig"}) ([@bib37]). When we incubated p31(comet) + C-MAD2^R133A^ with TRIP13, the p31(comet):C-MAD2 complex that initially forms was dissociated, and C-MAD2^R133A^ was converted to the open conformer ([Figure 7D](#fig7){ref-type="fig"}). This conversion depended on active TRIP13, ATP, and p31(comet). Despite a high rate of ATP hydrolysis, the TRIP13^W221A^ pore-loop mutant was unable to catalyze MAD2 conversion, illustrating that pore loop integrity is critical for MAD2 conformational conversion. To directly measure the catalytic activity of TRIP13, we titrated the enzyme and monitored C-MAD2^R133A^ to O-MAD2^R133A^ conversion. At 37°C, a single TRIP13 hexamer catalyzes the conversion of 1.9 ± 0.2 MAD2 molecules per minute ([Figure 7E](#fig7){ref-type="fig"}). Combining this measurement with TRIP13\'s fully-stimulated ATPase activity in these conditions (16.7 ± 0.3 ATP min^−1^ per hexamer; [Figure 7G](#fig7){ref-type="fig"}), we estimate that TRIP13 hydrolyzes 8--10 ATP\'s per MAD2 conformational conversion. This number is similar to several prior measurements of NSF-mediated SNARE complex disassembly (6--50 ATP per event, depending on experimental conditions) ([@bib9]; [@bib52]; [@bib58]) or ClpX-mediated unfolding of a small model substrate (∼150 ATP) ([@bib6]), likely reflecting that MAD2 conformational conversion may require only a local perturbation of the safety-belt motif, rather than complete unfolding (see 'Discussion'). This idea would fit with recent work indicating that NSF unfolds its substrates in a single step, using the energy from multiple ATP hydrolysis events to build up tension within the hexamer, then promoting a critical conformational change that results in SNARE complex disassembly ([@bib52]). A similar 'spring-loaded' mechanism in TRIP13 could enable the enzyme to catalyze conversion/disassembly of unliganded C-MAD2 or its complexes with partner proteins such as CDC20 with similar efficiency; alternatively, if MAD2 conformational conversion requires several rounds of ATP hydrolysis, the energy requirements for disassembly of ligand-stabilized MAD2 may be significantly higher than the 8--10 ATP we measured for C-MAD2^R133A^ conformational conversion.

Finally, we tested the ability of p31(comet) mutants that disrupt binding to either MAD2 or TRIP13 to support MAD2 conformational conversion. The MAD2-binding mutant (Q86A/F193A) and two TRIP13-binding mutants (Δ159--164 or P230A/K231A) each modestly reduced MAD2 conversion compared to wild-type p31(comet) ([Figure 7F](#fig7){ref-type="fig"}). Combinations of these mutants, however, almost completely eliminated MAD2 conversion ([Figure 7F](#fig7){ref-type="fig"}), illustrating that the adapter function of p31(comet) is critical for TRIP13 to recognize and convert C-MAD2 to O-MAD2.

Discussion {#s3}
==========

Our data show that Pch2/TRIP13 is a AAA+ ATPase with structural and mechanistic properties similar to both the 'classic remodelers' and the bacterial protein unfoldase ClpX. First, the PCH-2 hexamer architecture shows close mechanistic parallels with ClpX, suggesting a shared mechanism for nucleotide-dependent conformational changes driving pore loop motions and substrate remodeling. Our structural and biochemical data suggest that Pch2/TRIP13 engages its substrates within the hexamer pore, and undergoes coordinated ATP hydrolysis-coupled conformational changes to mediate substrate unfolding. In contrast to ClpX, however, Pch2/TRIP13 does not completely unfold its HORMA domain protein substrates. Rather, we have shown that TRIP13 catalyzes a much more subtle structural change, converting closed MAD2 to its open state. We propose that TRIP13 specifically unfolds the C-terminal safety belt region of MAD2, then allows it to refold into the open state. Given the mechanistic similarities between Pch2/TRIP13 and the processive unfoldase ClpX, however, an obvious question is how unfolding by Pch2/TRIP13 is controlled to achieve HORMA domain conformational conversion instead of complete unfolding.

The answer to this question may lie in the second aspect of Pch2/TRIP13\'s hybrid nature: its mode of substrate recognition, which is mediated by an NTD related to a family of 'classic remodelers' including NSF, p97, and PEX1. Importantly, as in NSF and p97, substrate recognition by Pch2/TRIP13 is indirect with p31(comet) acting as an adapter to deliver MAD2 to TRIP13. p31(comet) binds specifically to C-MAD2, meaning that once TRIP13 engages and unfolds the MAD2 safety belt, p31(comet) would cease to bind MAD2. This could destabilize the ternary complex, releasing partially-unfolded MAD2 and allowing its re-folding into the open conformation. As mentioned above, MAD2 safety belt unfolding could occur in a processive manner accompanied by multiple rounds of ATP hydrolysis by TRIP13, or could occur similarly to NSF, where recent work has indicated a single-step 'spring-loaded' mechanism for SNARE complex disassembly ([@bib52]). In the SAC, we propose that p31(comet) and TRIP13 catalyze a two-step MCC disassembly mechanism to inactivate the SAC ([Figure 8A,B](#fig8){ref-type="fig"}). First, p31(comet) displaces BUBR1 from MAD2, potentially causing its dissociation from MAD2:CDC20. The resulting p31(comet):MAD2:CDC20 complex is then recognized by TRIP13, which converts C-MAD2 to O-MAD2, thus disrupting binding to both p31(comet) and CDC20, and also preventing MCC re-assembly.10.7554/eLife.07367.018Figure 8.Model for SAC inactivation by p31(comet) and TRIP13.(**A**) Unattached kinetochores catalyze the assembly of the mitotic checkpoint complex (MCC) through the conversion of O-MAD2 to C-MAD2 and assembly with CDC20 (blue), BUBR1 (pink), and BUB3 (not shown). (**B**) After kinetochore-microtubule attachment, MCC assembly is halted. p31(comet) binds existing MCC and displaces BUBR1, then delivers C-MAD2:CDC20 to TRIP13 for conformational conversion and disassembly. The CDC20:BUBR1 interaction may be disrupted directly by p31(comet) or at a later point. (**C**) Scheme for TRIP13-mediated disassembly of HORMAD oligomers (blue) in meiosis. It is unknown whether HORMADs possess an open state analogous to O-MAD2. See [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"} for structures of O-MAD2, C-MAD2, C-HORMAD, and p31(comet) showing the safety-belt conformation in each state.**DOI:** [http://dx.doi.org/10.7554/eLife.07367.018](10.7554/eLife.07367.018)10.7554/eLife.07367.019Figure 8---figure supplement 1.HORMA domain structures in open and closed conformation.(**A**) Structures of human MAD2 in the open (left panel; PDB ID 1DUJ; \[[@bib35]\]), closed (middle panel; PDB ID 1S2H \[[@bib37]\]), and closed/peptide bound (right panel; PDB ID 1KLQ \[[@bib36]\]) conformations, with MAD2 in yellow, MAD2 safety belt (residues 160:205) colored dark green, and the MAD2-binding peptide (MBP-1) in blue. MAD2 residues 109--117, replaced with 'GSG' in loopless MAD2 ([@bib40]), are shown in blue in the O-MAD2 structure (left panel). (**B**) Structure of a meiotic HORMAD in the closed conformation (*C. elegans* HIM-3 bound to a peptide from HTP-3; PDB ID 4TZJ \[[@bib30]\]). The safety belt is colored dark green as in panel (**A**). (**C**) Structure of human p31(comet) (PDB ID 2QYF \[[@bib87]\]), with safety-belt motif (closed around its own C-terminus) shown in red, and the MAD2 binding surface (with residues 86 and 193 (numbering according to *M. musculus* p31(comet))) shown in blue. Side-chains for residues involved in TRIP13 binding (159--164 and 230--231) are shown in stick view. Cartoon representations of all structures are shown for reference.**DOI:** [http://dx.doi.org/10.7554/eLife.07367.019](10.7554/eLife.07367.019)

Essentially all free MAD2 in HeLa cells is in the open state ([@bib37]), but prior work ([@bib37]) and our own analysis ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}) indicates that while the two conformations are relatively stable at 4°C, at physiological temperatures essentially all O-MAD2 spontaneously converts to C-MAD2 within several hours. These data strongly suggest that cellular factors actively maintain MAD2 in the open state. We propose that a major role for TRIP13 and p31(comet) may be to counteract spontaneous O-MAD2 to C-MAD2 conversion, thus guarding against improperly-timed MCC assembly (which can occur outside mitosis given a supply of soluble C-MAD2 \[[@bib71]\]) and also ensuring a sufficient supply of O-MAD2 for SAC activation in prometaphase. An important remaining question is how the competing pathways for MCC assembly and disassembly are balanced and regulated throughout the cell cycle: do p31(comet) and TRIP13 constantly disassemble MCC at a low level during prometaphase and metaphase, with this activity becoming dominant only after new MCC assembly is ceased, or is the activity of p31(comet) and TRIP13 suppressed during metaphase by additional mechanisms? Recently it was shown that human p31(comet) is phosphorylated specifically in mitosis, and that phosphorylation lowers the affinity of p31(comet) for MAD2 ([@bib10]). While the phosphorylated residue (Ser102) is not universally conserved in p31(comet) orthologs, this result nonetheless represents one potential mechanism for suppressing TRIP13-mediated MCC disassembly specifically during mitosis.

The ability of TRIP13 to disengage the safety-belt motif of MAD2 strongly suggests a parallel mechanism for its remodeling/removal of HORMAD proteins along chromosomes in meiotic prophase ([Figure 8C](#fig8){ref-type="fig"}). We have previously shown that the meiotic HORMADs assemble into hierarchical head-to-tail complexes through safety-belt interactions, and that these interactions are crucial for meiotic DNA break formation, inter-homolog recombination, and chromosome segregation ([@bib30]). We have been unable, however, to detect direct interactions between PCH-2/TRIP13 and their putative HORMAD substrates, nor do these proteins stimulate PCH-2/TRIP13 ATPase activity (not shown). Thus, how the enzyme recognizes HORMAD complexes, whether a p31(comet)-like adapter is needed for this recognition, and what signals coordinate crossover formation with HORMAD complex remodeling and removal, remain important open questions. Finally, given the additional association of human *TRIP13* with a number of cancer types ([@bib34]; [@bib77]; [@bib4]), addressing the fundamental mechanistic questions regarding how this enzyme recognizes and remodels its substrates will be important for understanding TRIP13\'s multiple roles in human health and disease.

Materials and methods {#s4}
=====================

Sequence analysis {#s4-1}
-----------------

For sequence analysis of AAA+ ATPases, isolated AAA+ regions (large plus small domains, isolated D1 domain for p97/Cdc48 and NSF) were aligned with MAFFT ([@bib27]), a phylogenetic tree was constructed in JalView ([@bib82]), and the tree was visualized with Dendroscope ([@bib22]).

Protein expression and purification {#s4-2}
-----------------------------------

Full-length *C. elegans* PCH-2 and *M. musculus* TRIP13 were cloned from cDNA into a bacterial expression vector with an N-terminal TEV protease-cleavable His~6~ tag. Mutant constructs were generated by PCR-based mutagenesis: *C. elegans* PCH-2 ΔNTD consisted of residues 100--424, and the 'Pore loop AG' mutant replaced residues 218--227 with the protein sequence 'AGAAGAAAGA'. All PCH-2/TRIP13 mutants used for activity assays were expressed at levels similar to the wild-type proteins and migrated equivalently on a size-exclusion column, indicating that they are soluble and folded. The Walker A motif mutant K185Q of both PCH-2 or TRIP13, and the ΔNTD mutant of TRIP13, were not solubly expressed, precluding their analysis. For *C. elegans* MAD-2 (MDF-2) and CMT-1 (C41D11.5), and *M. musculus* MAD2 and p31(comet), full-length proteins were cloned from cDNA into a bacterial expression vector with an N-terminal TEV protease-cleavable His~6~ tag. Mutant constructs were generated by PCR-based mutagenesis: *M. musculus* MAD2 'loopless' replaced residues 109--117 with the protein sequence 'GSG' as in ([@bib40]) (see [Figure 8---figure supplement 1A](#fig8s1){ref-type="fig"}). For identification of highly conserved surface residues in p31(comet), 226 animal/plant p31(comet) sequences were aligned with MAFFT ([@bib27]) and conservation was mapped on the structure of p31(comet) bound to MAD2 ([@bib87]) using the CONSURF server ([@bib3]). All mutant constructs were generated by PCR-based mutagenesis. All mutant constructs used here (p31(comet), MAD2, and TRIP13) expressed at levels similar to wild-type, and migrated equivalently on a size-exclusion column (not shown), indicating that they were soluble and folded.

Proteins were expressed in *Escherichia coli* strain Rosetta 2 (DE3) pLysS (EMD Millipore, Billerica MA) at 20°C for 16 hr, then cells were harvested by centrifugation and resuspended in buffer A (25 mM Tris pH 7.5, 10% glycerol, 5 mM MgCl~2~) plus 300 mM NaCl, 5 mM imidazole, and 5 mM β-mercaptoethanol. Protein was purified by Ni^2+^-affinity (Ni-NTA agarose, Qiagen) then ion-exchange (Hitrap Q HP, GE Life Sciences, Piscataway NJ) chromatography. Tags were cleaved with TEV protease ([@bib74]), and cleaved protein was passed over a size exclusion column (Superdex 200, GE Life Sciences) in buffer A plus 300 mM NaCl and 1 mM dithiothreitol (DTT). Purified protein was concentrated by ultrafiltration (Amicon Ultra, EMD Millipore) to ∼10 mg/ml and stored at 4°C. For selenomethionine derivatization of PCH-2, protein expression was carried out in M9 minimal media supplemented with amino acids plus selenomethionine prior to IPTG induction ([@bib75]), and proteins were exchanged into buffer containing 1 mM *tris*(2-carboxyethyl)phosphine (TCEP) after purification to maintain the selenomethionine residues in the reduced state.

For size-exclusion chromatography coupled multi-angle light scattering (SEC-MALS), proteins were separated on a Superdex 200 10/300 GL size exclusion column (GE Life Sciences), their light scattering and refractive index profiles collected by miniDAWN TREOS and Optilab T-rEX detectors (Wyatt Technology, Santa Barbara CA), respectively, and their molecular weights calculated using ASTRA v. 6 software (Wyatt Technology).

Electron microscopy {#s4-3}
-------------------

For negative-stain EM, PCH-2 was passed over a size-exclusion column in EM buffer (buffer A without glycerol, and with added 1 mM DTT), then peak fractions were diluted to ∼0.01 mg/ml in EM buffer with or without 1 mM ATP. Samples were applied onto freshly glow discharged carbon coated copper grids, reduced to a thin film by blotting, and a 2% solution of uranyl formate negative stain was then immediately applied to the grid and blotted off from the same side. The negative stain process was repeated 3 times. Data were acquired using a Tecnai F20 Twin transmission electron microscope (FEI, Hillbsboro OR) operating at 200 kV. Images were automatically collected using the LEGINON system ([@bib68]). Images were recorded using a Tietz F416 4k × 4k pixel CMOS camera (TVIPS, Gauting, Germany).

Experimental data were processed by the APPION software package ([@bib33]). The defoci were estimated using ctffind3 ([@bib43]) and ACE2 ([@bib33]) and CTF correction was done by phase flipping the whole micrograph. Particles were selected automatically in APPION using DogPicker ([@bib51]; [@bib80]). After stack creation in APPION all datasets were prealigned and classified using 2-D maximum likelihood procedures and multivariate statistical analysis as implemented in XMIPP and IMAGIC ([@bib49]; [@bib76]; [@bib63]; [@bib55]). Resulting class averages were manually inspected and classes that represented noise or distorted particles were rejected. Final clustering was performed using XMIPP clustering 2D alignment (cl2d).

Crystallization and structure solution {#s4-4}
--------------------------------------

For crystallization, PCH-2 was exchanged into crystallization buffer (25 mM Tris pH 7.5, 5 mM MgCl~2~, 200 mM NaCl, 1 mM tris(2-carboxyethyl)phosphine \[TCEP\]), either without added nucleotide (Apo) or with 1 mM ADP or non-hydrolyzable ATP analogs (ATP-γS or AMP-PCP). Regardless of added nucleotides, PCH-2 formed large prism-shaped crystals after mixing 1:1 with 100 mM sodium citrate pH 5.6, 200 mM ammonium sulfate, and 15% PEG 3350. Crystals were cryoprotected by the addition of 20% glycerol, and flash-frozen in liquid nitrogen. Diffraction data were collected at synchrotron sources (see [Table 1](#tbl1){ref-type="table"}), and processed with HKL2000 ([@bib48]) or XDS ([@bib25]). All crystals were in space group C222~1~, with one PCH-2 hexamer per asymmetric unit. The structure was determined using phases obtained from a single-wavelength anomalous diffraction (SAD) dataset from a crystal grown from selenomethionine-derivatized protein. Automated XDS → SHELX → PHENIX for the SAD dataset was performed by the RAPD data-processing pipeline at the Advanced Photon Source NE-CAT beamline 24ID-E (<https://rapd.nec.aps.anl.gov/rapd>). 46 selenomethionine sites were identified using SHELX as implemented in hkl2map ([@bib59]), then supplied to the AutoBuild module of PHENIX ([@bib70]; [@bib1]), which located an addition 22 sites (for 68 total---66 sites would be expected for a hexamer of PCH-2, but in several cases two sites represented alternate rotamers for a single methionine residue), and calculated and refined phases using PHASER ([@bib42]) and RESOLVE ([@bib70]) (<http://www.solve.lanl.gov>). Initial sequence-threaded models of the large and small AAA domains were generated by the PHYRE2 server ([@bib28]) (<http://www.sbg.bio.ic.ac.uk/phyre2>) and manually placed to generate an initial model. Initial placement and refinement of this model allowed identification of twofold non-crystallographic symmetry, which was then used during early-stage map generation, model building, and refinement (final refinement was performed without non-crystallophic symmetry). Numerous rounds of manual rebuilding in Coot ([@bib12]) and refinement in phenix.refine ([@bib1]) against a high resolution native dataset resulted in improved maps, allowing us to manually build the NTDs. Data were highly anisotropic, showing significantly lower intensity (I/σ) and half--set correlation (CC~1/2~) ([@bib26]) along the c\* axis than along a\* and b\* ([Table 1](#tbl1){ref-type="table"} and [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). For refinement, the high-resolution native dataset processed to 2.3 Å with XDS was submitted to the UCLA Diffraction Anisotropy Server ([@bib65]) (<http://services.mbi.ucla.edu/anisoscale/>) for application of anisotropic cutoffs (2.3 Å along a\* and b\*, 3.2 Å along c\*). The final model consists of six PCH-2 monomers, with a total of 2214 residues modeled out of 2544 (6 × 424 residues); the model displays good geometry with 98.05% of residues in favored, and 99.77% of residues in allowed Ramachandran space ([Table 1](#tbl1){ref-type="table"}). All crystallographic software was installed and maintained through the SBGrid program ([@bib44]).

Protein--protein interaction assays {#s4-5}
-----------------------------------

For yeast two-hybrid analysis, full-length sequences for *M. musculus* TRIP13, MAD2, and p31(comet) (wild-type and mutants) were cloned into pGADT7 (Gal4 activation domain fusion: 'AD') and pBridge (Gal4 DNA binding domain fusion: 'BD') vectors (Clontech Laboratories, Mountain View CA). Plasmids were transformed into AH109 and Y187 yeast strains, and transformants selected on CSM -Leu (pGADT7) or CSM -Trp (pBridge) media. Haploid strains were mated overnight at room temperature, and diploids were selected on CSM -Leu-Trp media. Diploids were then patched onto CSM -Leu-Trp-His (low stringency; shown in [Figure 5B--C](#fig5){ref-type="fig"}) or CSM -Leu-Trp-His-Ade (high stringency; not shown, results consistent with low-stringency results) media, grown 3 days at 30°C, and imaged. For yeast three-hybrid analysis, p31(comet) was cloned into multiple cloning site \#2 of pBridge to express the untagged protein alongside the BD- and AD-fusion proteins.

For Ni^2+^ pulldown assays, 300 picomoles (9.3 μg) His~6~-tagged p31(comet) was mixed with 450 picomoles untagged MAD2 (10.7 μg) in 50 μl binding buffer (20 mM Tris-HCl pH 7.5 or 8.5, 200 mM NaCl, 20 mM imidazole, 1 mM β-mercaptoethanol, 5% glycerol, 0.1% NP-40), incubated 60 min 20°C, then 'load' samples (5 μl, 10%) were removed and samples were mixed with Ni-NTA magnetic beads (10 μl 5% suspension, Qiagen, Hilden, Germany) for 20 min 20°C. Samples were washed 3× with 1 ml binding buffer, then 25 μl SDS-PAGE loading buffer was added, samples were boiled, run on 12.5% SDS-PAGE gels and imaged by Coomassie staining.

For size-exclusion chromatography analysis of TRIP13 plus p31(comet):MAD2, equimolar amounts (10 nanomoles) of TRIP13^E253Q^, p31(comet), and C-MAD2^R133A^ were mixed in 300 μl total volume of gel filtration buffer (20 mM Tris-HCl pH 7.5, 300 mM NaCl, 10% Glycerol, 1 mM DTT) plus 2 mM ATP, and incubated on ice for 30 min before application on a size exclusion column (Superdex 200 Increase 10/300 GL, GE Life Sciences) in gel filtration buffer plus 0.1 mM ATP. For SEC-MALS analysis of selected complexes, the same protocol was followed except for addition of nucleotide to the column running buffer.

ATPase and MAD2 conversion assays {#s4-6}
---------------------------------

For ATPase assays with *C. elegans* PCH-2, optimal basal ATPase rates were obtained from protein treated during the Ni^2+^-affinity purification step with 0.8 M urea, which removes the two ADP molecules bound to each hexamer (as determined by UV absorbance; not shown), followed by addition of 50 mM ammonium sulfate to all subsequent purification steps (necessary for protein stability after ADP removal).

ATPase activity was determined at 27°C (except where indicated) using an enzyme-coupled assay ([@bib46]) adapted for a microplate reader ([@bib29]). 100 μl reactions contained assay buffer (25 mM Tris-HCl at pH 7.5 or 8.5 (see below), 200 mM NaCl, 10 mM MgCl~2~, 1 mM DTT, 5% glycerol) plus 2 mM ATP, 3 mM phosphoenolpyruvate, 20 U/ml lactate dehydrogenase (Sigma Aldrich, St. Louis MO), 20 U/ml pyruvate kinase (Sigma Aldrich), and 0.3 mM NADH. All PCH-2/TRIP13 constructs showed a strong dependence on pH with almost undetectable activity at pH 7.0 and below, and full activity at pH 8.5--9.5. For assays measuring stimulation of ATPase activity by p31(comet) and MAD2, assays were performed at pH 7.5 where basal activity was lower but substrate stimulation was robust. The assayed concentration of each PCH-2/TRIP13 construct was adjusted between 0.5 and 20 μM monomer, for the most accurate measurement of ATPase activity, depending on the assay. For TRIP13, which adopts multiple oligomeric states in solution, we verified that the ATP hydrolysis rate varies linearly between 0.625 and 10 μM TRIP13 (monomer concentration) at both pH 7.5 and 8.5, indicating that the protein is predominantly hexameric (and thus fully active) in our ATPase assay conditions (data not shown). Unless otherwise indicated, TRIP13 was equimolar with added p31(comet) and MAD2 (judging by TRIP13 monomer concentration). The decline of NADH absorbance at 340 nm was measured using a TECAN (Mannedorf, Switzerland) Infinite M1000 spectrophotometer in 384-well microplates. NADH oxidation rate was calculated from a linear fit to each time course and converted to ATP hydrolysis rates. For calculation of *K*~*m*~ and *k*~*cat*~, sampled were performed in triplicate with ATP concentration varying from 20 μM (lower bound for measuring decline in NADH absorbance) to 1 mM, and data were fit to the Michaelis-Menten equation (Y = (*V*~*max*~ × X)/(*K*~*m*~ + X)) using PRISM v. 6 (GraphPad Software, La Jolla CA).

For samples measuring TRIP13 ATPase activity after pre-incubation, proteins (4 μM concentration for all proteins) were pre-incubated for 2 hr at 20°C in assay buffer with or without ATP as above. Samples were then passed through a desalting spin column (Zeba-Spin, Thermo Scientific, Waltham MA) to remove remaining ATP and hydrolyzed ADP. Fresh ATP and coupled-assay master mix were then added and ATP hydrolysis measured as above.

To examine MAD2 conformational conversion by TRIP13, separately purified C-MAD2 monomer (R133A mutant), p31(comet), and TRIP13 were incubated at 20°C for 2 hr at 30 μM concentration (sixfold molar excess of p31(comet) and MAD2 to TRIP13 hexamers), in ATPase assay buffer (pH 7.5) with or without 2 mM ATP (166 μl reaction volume). Samples were diluted to 50 mM NaCl by the addition of buffer without NaCl, then loaded onto a 1 ml HiTrap Q HP column (GE Life Sciences) and eluted with a gradient to 400 mM NaCl. Fractions were collected, analyzed by SDS-PAGE and visualized by Coomassie staining.

For measurement of MAD2 conversion rate by TRIP13 ([Figure 7E,F](#fig7){ref-type="fig"}), pre-incubations were performed for 30 min at 37°C with 30 μM p31(comet), 30 μM MAD2 enriched for C-MAD2 (approximately 10 μM O-MAD2 and 20 μM C-MAD2), and the indicated amounts of TRIP13. Samples were separated by ion-exchange chromatography, and quantitation of Coomassie blue-stained SDS-PAGE bands was performed. Background-subtracted relative intensities of O-MAD2 vs C-MAD2 (lanes 6--7) was performed using ImageJ ([@bib56]), and ratios were converted to quantities based on the total (MAD2) of 30 μM. (O-MAD2) was plotted vs (TRIP13 hexamer) in the range of (TRIP13) where the reaction was not saturated (up to 0.2 μM TRIP13 hexamer). Linear regression fitting was performed with PRISM v. 6 (GraphPad Software).
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The following dataset was generated:

Ye Q, Corbett KD, 2015,Structure of C. elegans PCH-2,<http://www.pdb.org/pdb/explore/explore.do?structureId=4XGU>,Publicly available at RCSB Protein Data Bank (4XGU).

The following previously published datasets were used:

Glynn SE, Martin A, Nager AR, Baker TA, Sauer RT, 2009,Crystal structure of nucleotide-free hexameric ClpX,<http://www.rcsb.org/pdb/explore/explore.do?structureId=3HTE>,Publicly available at RCSB Protein Data Bank (3HTE).

Luo X, Fang G, Coldiron M, Lin Y, Yu H, Kirschner MW, Wagner G, 2000,Solution structure of the spindle assembly checkpoint protein human Mad2,<http://www.rcsb.org/pdb/explore/explore.do?structureId=1DUJ>,Publicly available at RCSB Protein Data Bank (1DUJ).

Luo X, Tang Z, Xia G, Wassmann K, Matsumoto T, Rizo J, Yu H, 2004,The Mad2 spindle checkpoint protein possesses two distinct natively folded states,<http://www.rcsb.org/pdb/explore/explore.do?structureId=1S2H>,Publicly available at RCSB Protein Data Bank (1S2H).

Luo X, Tang Z, Rizo J, Yu H, 2002,The Mad2 Spindle Checkpoint Protein Undergoes Similar Major Conformational Changes upon Binding to Either Mad1 or Cdc20,<http://www.rcsb.org/pdb/explore/explore.do?structureId=1KLQ>,Publicly available at RCSB Protein Data Bank (1KLQ).

Kim Y, Rosenberg SC, Kugel CL, Kostow N, Rog O, Davydov V, Su TY, Dernburg AF, Corbett KD, 2014,Structure of C. elegans HIM-3 bound to HTP-3 closure motif-4,<http://www.rcsb.org/pdb/explore/explore.do?structureId=4TZJ>,Publicly available at RCSB Protein Data Bank (4TZJ).

Yang M, Li B, Tomchick DR, Machius M, Rizo J, Yu H, Luo X, 2007,Crystal structure of the Mad2/p31(comet)/Mad2-binding peptide ternary complex,<http://www.rcsb.org/pdb/explore/explore.do?structureId=2QYF>,Publicly available at RCSB Protein Data Bank (2QYF).
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Thank you for sending your work entitled "TRIP13 is a protein-remodeling AAA+ ATPase that catalyzes MAD2 conformation switching" for consideration at *eLife*. Your article has been favorably evaluated by John Kuriyan (Senior editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The following individuals responsible for the peer review of your submission have agreed to reveal their identity: Axel Brunger (Reviewing editor); Andreas Martin (peer reviewer). A further reviewer remains anonymous.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

This manuscript describes a crystal structure of the TRIP13/Pch2 ATPase, along with negative stain electron microscopy microcopy (low resolution class averages), and the reconstitution in vitro of a crucial role of the ATPase, the conversion of C-MAD2 to O-MAD2. There are two interesting new findings: a pronounced type of asymmetry in the PCH-2 (TRIP13 homolog) AAA+ ATPase -- two of the subunits in the hexametric arrangement are bound to sulfate, two are apparently apo, and two are bound to ADP, resulting in large conformational differences between the "small" subdomain of the AAA+ module.

A second important result is the finding that TRIP13 can induce a conformational change in its substrate MAD-2 ("closed" to "open"), via the adapter protein p31. This function of TRIP13 may play a role during mitotic and meiotic chromosome segregation. In summary, this work provides new insights into the structure and function of TRIP13/PCH-2. However, there were some concerns about the interpretation and generality of the asymmetry observed in the crystal structure, and about the ATP hydrolysis experiments, as well as numerous suggestions on discussion of results from other groups on other systems.

*Reviewer \#1*:

1\) [Figure 1D](#fig1){ref-type="fig"} implies that AAA domains A and D are in the apo state. Is this correct? Are there conformational differences between apo and ADP bound states?

2\) Is it certain that A and D are apo? Please provide simulated annealing omit maps of the nucleotide binding regions of each of the six subunits.

3\) Figure 2--figure supplement 2: The comparison to ClpX is problematic since in that structure all subunits were in the apo state.

4\) [Figure 4](#fig4){ref-type="fig"}: does p31 interact with TRIP13 alone? In the case of NSF/aSNAP/SNARE, the adapter aSNAP does not interact with NSF alone.

5\) The negative-stain EM studies are rather low resolution, and no 3D reconstruction was attempted. It should be made clear in the text that these results are rather tentative considering the lack of a 3D reconstruction and the lack of a resolution estimate.

6\) There are too many supplementary figures, making it hard to read this paper. *eLife* discourages use of supplementary figures unless they represent raw data or repeat data. The authors are encouraged to restructure all their figures into a well-organized set of main figures with minimal use of supplementary figures.

Other comments to consider:

*Reviewer \#1*:

1\) Reference to Cipriano et al.: although Cipriano et al. measured 60 ATPs, others measured 10 ATPs (Shah, N., Colbert, K. N., Enos, M. D., Herschlag, D., & Weis, W. I. (2015). Three αSNAP and 10 ATP Molecules are used in SNARE Complex Disassembly by N -ethylmaleimide-sensitive Factor (NSF). Journal of Biological Chemistry, 290, 2175-2188).

2\) Figure 4--figure supplement 4: which nucleotide state was used?

3\) Figure 7--figure supplement 7, panel A: there are two structures shown (open and closed conformations). Please provide the PDB IDs of both structures.

4\) [Table 1](#tbl1){ref-type="table"}: the B-factors of the anisotropic scale factor tensor should be provided.

*Reviewer \#2*:

1\) Introduction: The references [@bib19], [@bib30], [@bib35] should be, if not replaced, at least supplemented with the two references that actually described the safety belt of MAD2 as a dynamic structural element, i.e. Luo et al. Mol. Cell 2002 and Sironi et al. EMBO J. 2002 (not to be confused with Sironi et al. EMBO J 2001, see below).

2\) Tipton et al. (2013; JBC 286) were the first authors to demonstrate the interaction of BubR1 with C-MAD2 that p31comet interferes with. The authors may elect to cite this paper alongside [@bib7]. The other two cited papers, albeit excellent, do not demonstrate the point the authors are discussing, i.e. the separation of C- MAD2 from BubR1. The reason to make this point is that the authors cite literature demonstrating a role of p31comet in MCC disassembly in a somewhat arbitrary and selective manner: there are quite a few additional papers making the point in addition to [@bib84] and it is immediately clear why the authors pick one but not the others.

3\) Discussion, first paragraph: The authors adopt an interpretation of the relative stability of O-MAD2 and C-MAD2 that is based on the studies of [@bib37]. There is a second interpretation, discussed by Mapelli et al. COSB 2007, in which O-MAD2 is seen as being more stable than empty (without a ligand) C-MAD2, but much less stable than ligand-bound C-MAD2. In this view, O-MAD2 is not a metastable state, but rather the stable state of MAD2 in the absence of a binding partner. The authors should consider that both the dimerization of MAD2 (even residual dimerization as in the R133A mutant) and the binding of C-MAD2 to p31comet (which they use in their assay) influence very dramatically the O-MAD2:C-MAD2 equilibrium, and that measuring the relative energy of these two states is therefore very complex. These considerations should probably reverberate also on the authors\' discussion on the amount of ATP used for the conversion reaction. If a ligand (e.g. Cdc20) were bound to C-MAD2, the stability of C-MAD2 would be much higher and probably the amount of ATP required for the conversion would be correspondingly higher. My feeling is that the low ATP requirements reported by the authors are essentially due to the fact that the empty C-MAD2 substrate they use is much less stable than a C-MAD2 bound to a substrate, and that all the energy essentially goes in disrupting the considerable stabilization to the C-MAD2 conformation provided by p31comet.

*Reviewer \#3*:

1\) TRIP13/PCH-2 is presented as a new AAA+ family, based on the observation that its N-terminal domain resembles those of classic remodelers, whereas its AAA+ domain shows stronger similarities to the HCLR clade of enzymes. The authors repeatedly emphasize that classic remodelers have a diverged mechanism for ATP-driven conformational changes, primarily due to the lack of a sensor-II Arg. However, to my knowledge there is no existing literature or strong data yet indicating a fundamental difference in mechanisms. Even the exact role of the sensor-II Arg is still unclear. Studies on Hsp104 suggested that the sensor-II Arg in NBD2 provides some extra nucleotide-binding energy but does not act to sense differences between nucleotides (Hattendorf and Lindquist, PNAS 99, 2002). In contrast, a sensor-II Arg mutation in ClpX allows normal ATP- or ADP binding but apparently prevents sensing of the nucleotide state (Joshi et al., NSMB 11, 2004).

The authors also discuss the distinctly asymmetric hexamer architecture of PCH-2 as an indication for a structural mechanism that is distinct from "classic remodelers". However, FtsH, a member of the classic clade of AAA+ enzymes, also crystallized as an asymmetric hexamer that resembled a dimer of trimers (Bieniossek et al., PNAS 103, 2006). There may be several different reasons why some AAA+ enzymes crystallize in 2-fold symmetric hexamers, like TRIP13/PCH-2 or ClpX, whereas others are more symmetric or have a continuous spiral staircase arrangement of subunits. As shown by EM studies in this manuscript, ATP binding can already significantly influence ring symmetry, and substrate binding in the central pore may induce additional changes in subunit arrangement or vertical registers. Even for ClpX, for which there are numerous structures and functional data both in bulk and at the single-molecule level, it remains unclear whether during substrate processing the hexamer maintains a 2-fold symmetry or adopts a conformation that contains a continuum of nucleotide states and a corresponding spiral staircase arrangement of pore-loops around the ring.

I therefore suggest that the authors focus on the obvious differences and similarities in structure and sequence between TRIP13/PCH-2 and the HCLR or classic clades (including the sensor-II motif and Arg finger), without speculating and claiming too much about potential differences in the mechanisms of ATP-hydrolysis coupled conformational changes.

Related to this, the authors state: "Mutation of the putative Sensor-2 residue R385 in PCH-2 also results in the loss of nucleotide binding, illustrating the importance of this residue and further supporting a ClpX-like mechanism...".

As mentioned above, ClpX with a mutation of the sensor-II Arg still has near wild-type affinity for ATP and ADP, and the authors should correct or clarify their statement to prevent confusion.

2\) Even though it is tempting and reasonable to interpret the PCH-2 crystal structure with respect to potential structural intermediates adopted by individual subunits during the ATPase cycle, the authors should more strongly consider and discuss that this is still "only" an empty/ADP-bound structure. As indicated by the presented negative-stain EM as well as several previous studies on related AAA+ enzymes, ATP binding to the hexamer may significantly affect subunit conformations and ring topology. I assume the authors unsuccessfully tried to solve a PCH-2 crystal structure in the presence of a non-hydrolyzable ATP analog or for the Walker-B mutant in the presence of ATP, and therefore turned to negative stain EM. It would be worth mentioning that the crystallization of the ATP-bound state was unsuccessful.

3\) In their discussion of potential nucleotide-driven conformational changes of PCH-2, pore-loop movements, and the strong similarities to the ClpX motor (in the subsection headed "Nucleotide-driven conformational changes in the PCH-2 hexamer" and [Figure 2F, G](#fig2){ref-type="fig"}) the authors may include a recent paper by the Sauer group, indicating highly coordinated gripping and conformational changes of subunits in the ClpX hexamer (Iosefson et al., Nat Chem Bio 11, 2015). This is particularly relevant for the model of axial pore loop movements presented in [Figure 2G](#fig2){ref-type="fig"}.

4\) The authors performed Michaelis-Menten analyses and calculated *k*~*cat*~ for ATP hydrolysis by PCH-2 and TRIP13 ([Figure 3](#fig3){ref-type="fig"}). In the legend for Figure 1--figure supplement 2 it is mentioned that TRIP13 adopts a mixture of oligomeric states that shifts to higher molecular weight oligomers upon addition of ATP. For an accurate calculation of *k*~*cat*~ the question remains: how much TRIP13 was present in hexameric versus other states? It may be useful to measure the dependence of ATP hydrolysis on TRIP13 concentration to get an idea about the Kd for hexamerization and thereby increase confidence in the calculated *k*~*cat*~ value.

For the measurement of C-MAD2 substrate turnover the authors varied the TRIP13 concentration and observed a linear dependence ([Figure 6E](#fig6){ref-type="fig"}), which suggests that the oligomeric state of TRIP13 did not change between 50 and 200 nM. However, it is possible that binding of p31/C-MAD2 to TRIP13 stabilizes the hexamer, especially because the single bound substrate-adaptor complex may bridge several TRIP13 subunits. It would therefore still be reasonable to assess the TRIP13-concentration dependence of ATP hydrolysis and get an idea about the extent of hexamers present under the experimental conditions used in the ATPase assay.

5\) In the legend to Figure 1--figure supplement 2 the authors mention that the E253Q mutant of TRIP13 is predominantly hexameric both in the presence and the absence of ATP, suggesting that the mutation itself stabilizes the hexameric state. How did the authors determine that this mutant is indeed nucleotide-free when purified? Like other AAA+ enzymes TRIP13 may hold on to nucleotide during purification, even more so when it is hydrolysis-dead due to the Walker-B mutation.

6\) It is a bit of a concern that the ATP-hydrolysis activity of PCH-2/TRIP13 is 90% inhibited at pH 7.5 compared to pH 8.5, and that the ATPase stimulation by p31/C-MAD2 can only be observed under these conditions. The authors should try to explain this behavior, as one would expect that the motor respond with a similar relative stimulation to the presence substrate in the central pore, independent of the pH and the corresponding basal ATPase rate. Does p31/C-MAD2 bind to TRIP13 with similar affinities at both pH 7.5 and 8.5? Currently there is no information in the figure legends or Materials and methods about the detailed buffer conditions used for SEC analyses of TRIP13/p31/MAD2 complex formation presented in [Figure 4E](#fig4){ref-type="fig"} and Figure 4--figure supplement 3 and 4.

The authors should for instance rule out that the observed ATPase stimulation by p31/C-MAD2 at pH 7.5 is simply due to a stabilization of the hexamer.

7\) The authors show that only one p31/MAD2 complex binds to the TRIP13 hexamer, despite the presence of 6 N-terminal domains. A substrate delivery model is suggested in which p31 transiently interacts with the TRIP13 N-terminal domain before MAD2 directly binds in the central pore. However, currently this is largely speculation, and the authors should test this model by assessing the complex formation for the W221A pore loop mutant of TRIP13.

8\) It is described in Materials and methods that "...optimal basal ATPase rates were obtained from protein treated during the Ni^2+^-affinity purification step with 0.8 M urea, which removes the two ADP molecules bound to each hexamer...".

It is unclear to me why the co-purified ADP needed to be removed prior to ATPase measurements, during which ADP is constantly generated and quickly turned into ATP by the regeneration system. Is this stripping step necessary to more accurately measure the PCH-2 concentration by UV absorbance? Or does PCH-2 with 2 bound ADP represent a trapped, inactive form of the hexamer, which may also be prevented by purifying PCH-2 in the presence of ATP?

9\) The ATPase measurements for the W221A mutant of TRIP13 showed absolutely no response to the presence of p31 and MAD2 at 27°C ([Figure 5B](#fig5){ref-type="fig"}), but at 37°C there is a more than 30% increase in hydrolysis activity ([Figure 6--figure supplement 1C](#fig6s1){ref-type="fig"}). The authors should try to explain those temperature-dependent differences in behavior.

10\) In the Discussion section the authors discuss TRIP13\'s mode of substrate recognition, which seems to include an initial interaction of the p31 adaptor with the TRIP13 N-terminal domain, before the MAD2 substrate binds in the central pore. The authors state: "its mode of substrate recognition, which parallels not ClpX but a family of 'classic remodelers' including NSF, p97, and Pex1." I am sure the Corbett group is aware that many ClpX substrates with N-terminal degradation signals initially interact with the ClpX N-terminal domain before they are transferred to the central pore, and ClpX adaptors also bind to the N-terminal domain for substrate delivery to the central pore. The overall process of substrate delivery to TRIP13 thus appears to strongly parallel the mechanisms of ClpX, even though there are differences in the architecture of the N-terminal domains. The authors should clarify or correct their statement to prevent confusion.

11\) There is a mistake in a figure reference in the last paragraph of the subsection headed "p31(comet) functions as an adapter between MAD2 and TRIP13". The sentence "Semi-quantitative analysis of Coomassie-stained gels, and light-scattering based molecular-weight measurements on this peak, revealed that for each TRIP13E235Q hexamer, about 1 copy of each protein was shifted into the TRIP13 peak ([Figure 4D](#fig4){ref-type="fig"}, Figure 4--figure supplement 4)..." should reference [Figure 4E](#fig4){ref-type="fig"}, not 4D.

10.7554/eLife.07367.021

Author response

Reviewer \#1:

*1)* [*Figure 1D*](#fig1){ref-type="fig"} *implies that AAA domains A and D are in the apo state. Is this correct? Are there conformational differences between apo and ADP bound states*?

Chains A and D are both bound to a SO~4~^-^ ion; we apologize for the confusion. We have restructured [Figure 1D](#fig1){ref-type="fig"} (now 2A) to include an explicit note of nucleotide/SO~4~^-^ binding in each active site. We now also provide views of all six active sites (with *F*~*o*~*-F*~*c*~ simulated annealing omit maps) in [Figure 2--figure supplement 1B](#fig2s1){ref-type="fig"}. As for conformation, while chains A/D are bound to SO~4~^-^ and chains B/E are bound to ADP, their conformations are essentially identical, with an overall Cα r.m.s.d. of about 2 Å between them. Chains C/F are also bound to SO~4~^-^ but show a 70° rotation of the small AAA domain relative to the large AAA domain.

*2) Is it certain that A and D are apo? Please provide simulated annealing omit maps of the nucleotide binding regions of each of the six subunits*.

We performed simulated annealing refinement (torsion angle refinement, starting temperature 2500 K) in phenix.refine on a model with all nucleotides, SO~4~^-^ ions, and water atoms removed. The results show clear density for SO~4~^-^ ion in chains A, C, D and F, and ADP in chains B and E. The final *F*~*o*~*-F*~*c*~ maps from the SA refinement can be seen in [Figure 2--figure supplement 1B](#fig2s1){ref-type="fig"}.

*3) Figure 2--figure supplement 2: The comparison to ClpX is problematic since in that structure all subunits were in the apo state*.

It is true that the ClpX structure cited in our original submission is in the apo state, but later structural work from the Sauer group showed that this hexamer conformation is compatible with nucleotide binding, with ATPγS bound to the active sites of the four "closed" (referred to by the Sauer group as nucleotide-"loadable") chains: A, B, D, and E (PDB 4I81, Stinson et al. Cell 2013). The ATPγS-bound ClpX structure supports the idea that in both ClpX and in PCH-2, the closed/loadable conformation represents a nucleotide-bound like state, and the open/unloadable conformation represents an Apo state. Thus, while the actual nucleotide-binding state of both ClpX structures differs from our PCH-2 Apo/ADP structure, the information these structures possess regarding the likely motions that occur during nucleotide binding/hydrolysis/release is comparable.

To make this point clearer in the text, we have added a reference and a discussion of the later work showing the ClpX ATPγS structure (in the subsection headed "Nucleotide-driven conformational changes in the PCH-2 hexamer"). We have not altered [Figure 3](#fig3){ref-type="fig"} (was Figure 2--figure supplement 2) to include the ClpX ATPγS structure since in that structure, the pore loops were not as well-ordered as in the Apo structure.

*4)* [*Figure 4*](#fig4){ref-type="fig"}*: does p31 interact with TRIP13 alone? In the case of NSF/aSNAP/SNARE, the adapter aSNAP does not interact with NSF alone*.

p31(comet) does indeed interact with TRIP13 on its own, albeit more weakly than when it is bound to C-MAD2. This can be seen in our (and others') yeast two-hybrid results showing a binary interaction in the absence of MAD2, and our size-exclusion chromatography analysis ([Figure 5--figure supplement 1](#fig5s1){ref-type="fig"}) showing that a small amount of p31(comet) shifts into the TRIP13 hexamer peak in the absence of MAD2. We propose that p31(comet) is able to recognize and bind the TRIP13 NTD without MAD2, but that MAD2 engaging within the TRIP13 hexamer pore further stabilizes the interaction.

*5) The negative-stain EM studies are rather low resolution, and no 3D reconstruction was attempted. It should be made clear in the text that these results are rather tentative considering the lack of a 3D reconstruction and the lack of a resolution estimate*.

We have made it clearer in the text that the EM analysis is very limited, given the dominance of top-down views in the data, and the lack of a 3D reconstruction. Nonetheless, we feel that these data are worth including as an indication that the PCH-2 hexamer can undergo what appear to major conformational changes upon nucleotide binding.

*6) There are too many supplementary figures, making it hard to read this paper.* eLife *discourages use of supplementary figures unless they represent raw data or repeat data. The authors are encouraged to restructure all their figures into a well-organized set of main figures with minimal use of supplementary figures*.

We have significantly streamlined the figures to make the narrative easier to follow. There are now eight main figures, each with two or fewer figure supplements, and less overall repetition of data.

*Other comments to consider*:

Reviewer \#1:

*1) Reference to Cipriano et al.: although Cipriano et al. measured 60 ATPs, others measured 10 ATPs (Shah, N., Colbert, K. N., Enos, M. D., Herschlag, D., & Weis, W. I. (2015). Three αSNAP and 10 ATP Molecules are used in SNARE Complex Disassembly by N -ethylmaleimide-sensitive Factor (NSF). Journal of Biological Chemistry, 290, 2175-2188)*.

We thank the reviewer for pointing out this reference; we have cited it alongside Cipriano et al. It does seem that in the Shah experiment, the higher observed efficiency may be partly due to the trimeric αSNAP construct used; nonetheless, the measured number of ∼10 ATPs per event likely represents maximally efficient NSF-mediated SNARE disassembly.

*2) Figure 4--figure supplement 4: which nucleotide state was used*?

In these experiments, proteins were mixed in the presence of 2 mM ATP (TRIP13^E253Q^ was used to both stabilize the TRIP13 hexamer and eliminate hydrolysis), then the size exclusion column was run in buffer lacking nucleotide (while the SEC-MALS runs were performed without nucleotide in the running buffer to maximize signal/noise; the more comprehensive set of SEC runs were performed with 0.1 mM ATP in the running buffer. The consistent results between these conditions indicate that TRIP13^E253Q^ is likely stably bound to ATP after pre-incubation). We realized that a description of these experiments had been omitted from the Methods section; this has been remedied in the revised version of the manuscript.

*3) Figure 7--figure supplement 7, panel A: there are two structures shown (open and closed conformations). Please provide the PDB IDs of both structures*.

In the original version of this figure, both O-MAD2 (loopless) and C-MAD2 were taken from the MAD2 "conformational dimer" structure (PDB ID 2V64, [@bib40]). We have now altered this figure to use the first reported structure of MAD2 in each conformation, and the PDB ID and reference for each panel is noted in the figure legend (now [Figure 8--figure supplement 1A](#fig8s1){ref-type="fig"}). We also now include the structure of unliganded C-MAD2 in this figure.

*4)* [*Table 1*](#tbl1){ref-type="table"}*: the B-factors of the anisotropic scale factor tensor should be provided*.

We have added the requested data to [Table 1](#tbl1){ref-type="table"}, along with the CC~1/2~ scores for each direction at the maximum resolution used for the elliptical data cutoffs.

Reviewer \#2:

*1) Introduction: The references* [@bib19], [@bib30], [@bib35] *should be, if not replaced, at least supplemented with the two references that actually described the safety belt of MAD2 as a dynamic structural element, i.e. Luo et al. Mol. Cell 2002 and Sironi et al. EMBO J. 2002 (not to be confused with Sironi et al. EMBO J 2001, see below)*.

We thank the reviewer for pointing out this error, and have added the two noted references. We have also kept the citations of Hara and Kim, as they are examples of distinct HORMA domain protein families binding their partners in a manner equivalent to MAD2.

*2) Tipton et al. (2013; JBC 286) were the first authors to demonstrate the interaction of BubR1 with C-MAD2 that p31comet interferes with. The authors may elect to cite this paper alongside* [@bib7]*. The other two cited papers, albeit excellent, do not demonstrate the point the authors are discussing, i.e. the separation of C-MAD2 from BubR1. The reason to make this point is that the authors cite literature demonstrating a role of p31comet in MCC disassembly in a somewhat arbitrary and selective manner: there are quite a few additional papers making the point in addition to* [@bib84] *and it is immediately clear why the authors pick one but not the others*.

The reviewer is absolutely correct that our original submission did not properly reference the p31(comet) literature, and did not properly credit the several groups that have contributed in this area. We have restructured this section of the Introduction, added the Tipton et al. (2011) JBC reference noted, and also added several other references from different groups that show p31(comet)'s importance for SAC inactivation.

*3) Discussion, first paragraph:. The authors adopt an interpretation of the relative stability of O-MAD2 and C-MAD2 that is based on the studies of* [@bib37]*. There is a second interpretation, discussed by Mapelli et al. COSB 2007, in which O-MAD2 is seen as being more stable than empty (without a ligand) C-MAD2, but much less stable than ligand-bound C-MAD2. In this view, O-MAD2 is not a metastable state, but rather the stable state of MAD2 in the absence of a binding partner. The authors should consider that both the dimerization of MAD2 (even residual dimerization as in the R133A mutant) and the binding of C-MAD2 to p31comet (which they use in their assay) influence very dramatically the O-MAD2:C-MAD2 equilibrium, and that measuring the relative energy of these two states is therefore very complex. These considerations should probably reverberate also on the authors\' discussion on the amount of ATP used for the conversion reaction. If a ligand (e.g. Cdc20) were bound to C-MAD2, the stability of C-MAD2 would be much higher and probably the amount of ATP required for the conversion would be correspondingly higher. My feeling is that the low ATP requirements reported by the authors are essentially due to the fact that the empty C-MAD2 substrate they use is much less stable than a C-MAD2 bound to a substrate, and that all the energy essentially goes in disrupting the considerable stabilization to the C-MAD2 conformation provided by p31comet*.

The reviewer makes an excellent point, and we had not fully considered the complexity of the MAD2 energy landscape. To clarify the picture somewhat, we sought to determine the equilibrium levels of open and closed MAD2^R133A^ in vitro, using our ion-exchange chromatography assay. We performed these tests in the absence of any binding partners (which we agree do significantly stabilize the C-MAD2 conformation). We incubated purified O-MAD2 or C-MAD2 24 hours at 37°C, then separated them by ion-exchange and quantified their relative levels. We find that both samples converge to ∼15% O-MAD2 and ∼85% C-MAD2 ([Figure 7--figure supplement 1](#fig7s1){ref-type="fig"}). These results indicate that whatever the reason (dimerization, even residual dimerization as in MAD2^R133A^, could certainly promote conversion or at least stabilize the closed state), C-MAD2 is the preferred state in solution even in the absence of binding partners. Because of the complexity of this issue and our still-limited data, however, we have refrained from stating outright that C-MAD2 is more thermodynamically stable than O-MAD2.

Based on the above data and prior findings that O-MAD2 spontaneously converts to C-MAD2 ([@bib37] and other references), we feel that our proposal that TRIP13 and p31(comet) may serve to maintain cellular MAD2 in the open state is still valid. Indeed, as noted by [@bib37] and now explicitly noted in our discussion, essentially all free MAD2 in a HeLa cell extract is in the open state. Unless MAD2's inherent conformational equilibrium is fundamentally different inside the cell versus outside, there will be a continuous (albeit slow) conversion of O-MAD2 to C-MAD2, which must be counteracted to avoid aberrant SAC activation, etc.

Apart from the above discussion, we agree with the reviewer that unliganded C-MAD2 is likely much less stable than liganded (or otherwise bound, e.g. to p31(comet) C-MAD2. We have added a sentence to the Results section (in the subsection headed "TRIP13 catalyzes the conversion of closed MAD2 to the open conformer") pointing this out, and noting that conformational conversion of liganded C-MAD2 may take significantly more energy than what we measured.

Reviewer \#3:

*1) TRIP13/PCH-2 is presented as a new AAA+ family, based on the observation that its N-terminal domain resembles those of classic remodelers, whereas its AAA+ domain shows stronger similarities to the HCLR clade of enzymes. The authors repeatedly emphasize that classic remodelers have a diverged mechanism for ATP-driven conformational changes, primarily due to the lack of a sensor-II Arg. However, to my knowledge there is no existing literature or strong data yet indicating a fundamental difference in mechanisms. Even the exact role of the sensor-II Arg is still unclear. Studies on Hsp104 suggested that the sensor-II Arg in NBD2 provides some extra nucleotide-binding energy but does not act to sense differences between nucleotides (Hattendorf and Lindquist, PNAS 99, 2002). In contrast, a sensor-II Arg mutation in ClpX allows normal ATP- or ADP binding but apparently prevents sensing of the nucleotide state (Joshi et al., NSMB 11, 2004)*.

We agree that the evidence for diverged mechanisms between the "classic remodelers" and other AAA+ proteins is not clear, so have re-worded the discussion of these points throughout the manuscript.

*The authors also discuss the distinctly asymmetric hexamer architecture of PCH-2 as an indication for a structural mechanism that is distinct from* "*classic remodelers*"*. However, FtsH, a member of the classic clade of AAA+ enzymes, also crystallized as an asymmetric hexamer that resembled a dimer of trimers (Bieniossek et al., PNAS 103, 2006). There may be several different reasons why some AAA+ enzymes crystallize in 2-fold symmetric hexamers, like TRIP13/PCH-2 or ClpX, whereas others are more symmetric or have a continuous spiral staircase arrangement of subunits. As shown by EM studies in this manuscript, ATP binding can already significantly influence ring symmetry, and substrate binding in the central pore may induce additional changes in subunit arrangement or vertical registers. Even for ClpX, for which there are numerous structures and functional data both in bulk and at the single-molecule level, it remains unclear whether during substrate processing the hexamer maintains a 2-fold symmetry or adopts a conformation that contains a continuum of nucleotide states and a corresponding spiral staircase arrangement of pore-loops around the ring*.

*I therefore suggest that the authors focus on the obvious differences and similarities in structure and sequence between TRIP13/PCH-2 and the HCLR or classic clades (including the sensor-II motif and Arg finger), without speculating and claiming too much about potential differences in the mechanisms of ATP-hydrolysis coupled conformational changes*.

We have restructured both the Results and Discussion sections on these points, with a clarified discussion of our findings and less speculation about the mechanistic uniqueness of Pch2/TRIP13.

*Related to this, the authors state:* "*Mutation of the putative Sensor-2 residue R385 in PCH-2 also results in the loss of nucleotide binding, illustrating the importance of this residue and further supporting a ClpX-like mechanism...*".

*As mentioned above, ClpX with a mutation of the sensor-II Arg still has near wild-type affinity for ATP and ADP, and the authors should correct or clarify their statement to prevent confusion*.

We have removed the reference to ClpX in this sentence, and instead simply point out that the loss of nucleotide binding affinity in the R385 mutant strongly supports its identification as a Sensor-2 motif.

*2) Even though it is tempting and reasonable to interpret the PCH-2 crystal structure with respect to potential structural intermediates adopted by individual subunits during the ATPase cycle, the authors should more strongly consider and discuss that this is still* "*only*" *an empty/ADP-bound structure. As indicated by the presented negative-stain EM as well as several previous studies on related AAA+ enzymes, ATP binding to the hexamer may significantly affect subunit conformations and ring topology. I assume the authors unsuccessfully tried to solve a PCH-2 crystal structure in the presence of a non-hydrolyzable ATP analog or for the Walker-B mutant in the presence of ATP, and therefore turned to negative stain EM. It would be worth mentioning that the crystallization of the ATP-bound state was unsuccessful*.

While our EM analysis was conducted alongside crystallization trials, the reviewer is correct that we tried extensively to determine the structure of nucleotide-bound PCH-2, so far without success. Generally, we found that regardless of the added nucleotide, the resulting crystals adopted the same form as that determined here. After determining the Apo/ADP structure and then developing a method to strip out the bound nucleotide (see response to question 8 below), we were likely more successful in exchanging the nucleotide, but thus far we have not obtained crystals of protein treated in this manner. We now note our unsuccessful attempts to determine the PCH-2 structure in the presence of nucleotides in the subsection headed "Nucleotide-driven conformational changes in the PCH-2 hexamer" of the revised manuscript.

*3) In their discussion of potential nucleotide-driven conformational changes of PCH-2, pore-loop movements, and the strong similarities to the ClpX motor (in the subsection headed "Nucleotide-driven conformational changes in the PCH-2 hexamer" and* [*Figure 2F, G*](#fig2){ref-type="fig"}*) the authors may include a recent paper by the Sauer group, indicating highly coordinated gripping and conformational changes of subunits in the ClpX hexamer (Iosefson et al., Nat Chem Bio 11, 2015). This is particularly relevant for the model of axial pore loop movements presented in* [*Figure 2G*](#fig2){ref-type="fig"}.

We have included this reference as well.

*4) The authors performed Michaelis-Menten analyses and calculated* k~cat~ *for ATP hydrolysis by PCH-2 and TRIP13 (*[*Figure 3*](#fig3){ref-type="fig"}*). In the legend for Figure 1--figure supplement 2 it is mentioned that TRIP13 adopts a mixture of oligomeric states that shifts to higher molecular weight oligomers upon addition of ATP. For an accurate calculation of* k~cat~ *the question remains: how much TRIP13 was present in hexameric versus other states? It may be useful to measure the dependence of ATP hydrolysis on TRIP13 concentration to get an idea about the Kd for hexamerization and thereby increase confidence in the calculated* k~cat~ *value*.

*For the measurement of C-MAD2 substrate turnover the authors varied the TRIP13 concentration and observed a linear dependence (*[*Figure 6E*](#fig6){ref-type="fig"}*), which suggests that the oligomeric state of TRIP13 did not change between 50 and 200 nM. However, it is possible that binding of p31/C-MAD2 to TRIP13 stabilizes the hexamer, especially because the single bound substrate-adaptor complex may bridge several TRIP13 subunits. It would therefore still be reasonable to assess the TRIP13-concentration dependence of ATP hydrolysis and get an idea about the extent of hexamers present under the experimental conditions used in the ATPase assay*.

As suggested by the reviewer, we measured the concentration dependence of TRIP13's basal ATPase activity at both pH 7.5 and 8.5. The results, seen in [Author response image 1](#fig9){ref-type="fig"} (from triplicate measurements), indicate that within the TRIP13 concentration range we can reasonably test at each pH, the ATPase rate varies linearly with TRIP13 concentration (R^2^ values for both linear regression fits were 0.998). The slopes of these lines, which correspond to ATP's hydrolyzed per minute per TRIP13 hexamer, are 3.36 at pH 7.5 and 8.64 at pH 8.5, close to the values reported in the manuscript. These data support the idea that wild-type TRIP13 is mostly hexameric in the ATPase assay conditions. We have noted this point in the Methods section (in the subsection headed "ATPase and MAD2 conversion assays") as unpublished data.10.7554/eLife.07367.022Author response image 1.**DOI:** [http://dx.doi.org/10.7554/eLife.07367.022](10.7554/eLife.07367.022)

*5) In the legend to Figure 1--figure supplement 2 the authors mention that the E253Q mutant of TRIP13 is predominantly hexameric both in the presence and the absence of ATP, suggesting that the mutation itself stabilizes the hexameric state. How did the authors determine that this mutant is indeed nucleotide-free when purified? Like other AAA+ enzymes TRIP13 may hold on to nucleotide during purification, even more so when it is hydrolysis-dead due to the Walker-B mutation*.

We were also concerned about this point, so have done some analysis to convince ourselves that TRIP13^E253Q^ is indeed "Apo" when purified. When we purify TRIP13^E253Q^ from *E. coli* (without adding nucleotides), the final size-exclusion step shows a major hexamer peak, and a minor monomer peak. During concentration and 4°C storage of the hexamer peak, extensive precipitation occurs, which can be eliminated by the addition of a nucleotide of our choice. This implies that the protein is not already bound to nucleotide when purified (or at least is not fully occupied), but is then stabilized upon the addition of nucleotides. Further, we have measured the UV absorbance spectrum for purified TRIP13^E253Q^ prior to nucleotide addition, and we obtain an A~260/280~ ratio of 0.651. From a theoretical calculation of TRIP13's UV absorbance from the spectra of Trp, Tyr, and Phe, we obtain a theoretical A~260/280~ ratio of 0.682 for Apo protein, 0.786 for a TRIP13 hexamer bound to two nucleotides (as in PCH-2), and 0.977 for a hexamer bound to six nucleotides. Therefore, we are confident that TRIP13^E253Q^ is in the Apo state when purified.

A useful comparison can be made to the case of PCH-2, which does stably bind two ADP molecules per hexamer through the purification, except if treated with small amounts of denaturant during the initial Ni^2+^ affinity step (see response to point 8 below). We can clearly observe the two bound ADP's, and their removal by denaturant treatment, by UV/Vis spectroscopy in that case.

*6) It is a bit of a concern that the ATP-hydrolysis activity of PCH-2/TRIP13 is 90% inhibited at pH 7.5 compared to pH 8.5, and that the ATPase stimulation by p31/C-MAD2 can only be observed under these conditions. The authors should try to explain this behavior, as one would expect that the motor respond with a similar relative stimulation to the presence substrate in the central pore, independent of the pH and the corresponding basal ATPase rate. Does p31/C-MAD2 bind to TRIP13 with similar affinities at both pH 7.5 and 8.5? Currently there is no information in the figure legends or Materials and methods about the detailed buffer conditions used for SEC analyses of TRIP13/p31/MAD2 complex formation presented in* [*Figure 4E*](#fig4){ref-type="fig"} *and Figure 4--figure supplement 3 and 4*.

*The authors should for instance rule out that the observed ATPase stimulation by p31/C-MAD2 at pH 7.5 is simply due to a stabilization of the hexamer*.

We agree that the pH dependence of PCH-2/TRIP13 activity and stimulation by p31(comet):MAD2 is initially somewhat confusing. Is not the case, however, that there is no observed stimulation of PCH-2/TRIP13 by p31(comet):MAD2 at pH 8.5; only that the stimulation factor is not as high. For example, a TRIP13 hexamer hydrolyzes ∼2.5 ATP/min in the basal state versus ∼11 when stimulated at pH 7.5 (4X stimulation), versus a basal rate of 9 ATP/min and stimulated rate of ∼19 ATP/min at pH 8.5 (2X stimulation; not shown in manuscript). The stimulated rates at each pH also agree well with the basal rate of TRIP13 W221A (11 ATP/min at pH 7.5, 19 ATP/min at pH 8.5). We interpret these results as indicating that at pH 8.5, even without p31(comet):MAD2, PCH-2/TRIP13 is working closer to its maximum capacity than at pH 7.5, so the observed stimulation is lower as a result. We feel that the basal and stimulated ATPase rates measured at pH 7.5 are more relevant to the cellular context; however when initially characterizing these enzymes' ATPase rates and *K*~*m*~/*k*~*cat*~ values, we sought to maximize the enzyme's basal hydrolysis rate for easier characterization.

As noted above, we have added a new section to the Methods describing the conditions for our size exclusion analyses. This analysis was indeed done at pH 7.5, close to the conditions used for ATPase stimulation of PCH-2/TRIP13.

To address the point about hexamer stabilization and its effects on ATPase stimulation, we note two points: 1) While the TRIP13 hexamer is unstable, PCH-2 is a stable hexamer in all conditions, and we see the same general trend in pH-dependent changes in stimulation for PCH-2 as TRIP13 (for PCH-2, 1.7-fold stimulation at pH 7.5 versus 1.2-fold stimulation at pH 8.5; not shown in manuscript). 2) As mentioned above, we tested the concentration dependence of ATP hydrolysis by TRIP13 at both pH 7.5 and 8.5, and the results indicate that in our ATPase assay conditions, TRIP13 is likely to be fully hexameric even in the absence of p31(comet):MAD2.

*7) The authors show that only one p31/MAD2 complex binds to the TRIP13 hexamer, despite the presence of 6 N-terminal domains. A substrate delivery model is suggested in which p31 transiently interacts with the TRIP13 N-terminal domain before MAD2 directly binds in the central pore. However, currently this is largely speculation, and the authors should test this model by assessing the complex formation for the W221A pore loop mutant of TRIP13*.

This is an excellent suggestion, and was indeed an experiment that we initially attempted. For these experiments, we have used the TRIP13^E253Q^ mutant, which forms a stable hexamer by size exclusion. We generated the TRIP13^E253Q/W221A^ double mutant in order to test the role of the pore loop in p31(comet):MAD2 binding but found that, unexpectedly, this mutant does not form a stable hexamer like the TRIP13^E253Q^ mutant (as judged by elution on a size exclusion column in the presence of nucleotide). Instead, its behavior appears more similar to both wild-type TRIP13 and TRIP13^W221A^, which both adopt a mixture of oligomeric states whose migration on a size-exclusion column is not clearly distinct from that of p31(comet):MAD2. Thus, we were unable to accurately judge complex formation in the TRIP13^E253Q/W221A^ double mutant using elution-volume shifts on a size exclusion column. We have now noted this result in the text at the end of the subsection entitled "p31(comet) functions as an adapter between MAD2 and TRIP13".

The behavior of the TRIP13^E253Q/W221A^ mutant is somewhat mysterious, and a full explanation will likely require a more comprehensive analysis of the *M. musculus* TRIP13^E253Q^ hexamer's conformation. We note that the TRIP13^W221A^ single mutant has comparable activity to fully-stimulated TRIP13, strongly supporting the notion that it can form active hexamers. Also, *C. elegans* PCH-2^W221A^ forms stable hexamers as in wild-type PCH-2, indicating that this mutant does not significantly disrupt PCH-2 structure. We are currently pursuing several avenues for structural analysis of TRIP13, which may explain how the W221A mutation can disrupt the stable hexamer state adopted by TRIP13^E253Q^.

*8) It is described in Materials and methods that* "*...optimal basal ATPase rates were obtained from protein treated during the Ni*^*2+*^*-affinity purification step with 0.8 M urea, which removes the two ADP molecules bound to each hexamer...*".

*It is unclear to me why the co-purified ADP needed to be removed prior to ATPase measurements, during which ADP is constantly generated and quickly turned into ATP by the regeneration system. Is this stripping step necessary to more accurately measure the PCH-2 concentration by UV absorbance? Or does PCH-2 with 2 bound ADP represent a trapped, inactive form of the hexamer, which may also be prevented by purifying PCH-2 in the presence of ATP*?

Based on our experience with PCH-2, we believe that the reviewer is most likely correct in labeling the ADP/Apo state we crystallized as a "trapped, inactive form of the hexamer." This has stymied crystallization of PCH-2 with other nucleotides (as noted above), as well as initial ATPase activity assays. We found that the urea treatment gave maximally active PCH-2, likely because the ADP/Apo state is remarkably stable; the two ADP molecules imaged in our crystal structure remained bound to PCH-2 during a two-day protein purification (including four chromatography steps and multiple buffer exchanges) and several days in the crystallization conditions. It is likely that incubation in an ATP-regenerating system would eventually give maximally active protein, but the amount of time required for this activation would be prohibitive.

As can be observed in [Author response image 2](#fig10){ref-type="fig"}, the A~280~ of purified PCH-2 changes very little after stripping out the bound nucleotides; however, it is clear from changes in A~260/280~ ratio that the treatment does indeed have the desired effect.

[Author response image 2](#fig10){ref-type="fig"} describes the stripping of nucleotide from PCH-2^E253Q^, intended for crystallization trials. The results for wild-type PCH-2 are equivalent.10.7554/eLife.07367.023Author response image 2.UV Absorbance Spectra of PCH-2.The denatured UV absorbance spectrum of full-length PCH-2^E253Q^ was collected after standard purification from *E. coli* overexpression (red line), or purification with a transient 0.8 M urea wash followed by stabilization of the protein in buffer containing 50 mM ammonium sulfate (blue line). The A~260/280~ ratios of the urea-treated sample agreed with the theoretical value calculated for PCH-2 protein based on amino acid content (0.689 measured versus 0.701 theoretical), and the ratio for untreated PCH-2 matched the theoretical value calculated for a PCH-2 hexamer bound to two ADP molecules (0.825 measured versus 0.818 theoretical), as observed in our crystal structure of untreated wild-type protein. We normalized the two spectra in the 295-300 nm range, which is not affected by bound nucleotides, then subtracted them to obtain a residual spectrum (green), which closely matched a scaled spectrum of ADP (black circles). Quantitation of ADP amounts from the residual spectrum using the molar absorbance of ADP (15,400 M^-1^cm^-1^ at 260 nm) and PCH-2 (38,400 M^-1^cm^-1^ at 280 nm) indicated that urea treatment removes ∼2.3 ADP molecules per PCH-2 hexamer.**DOI:** [http://dx.doi.org/10.7554/eLife.07367.023](10.7554/eLife.07367.023)

*9) The ATPase measurements for the W221A mutant of TRIP13 showed absolutely no response to the presence of p31 and MAD2 at 27°C (*[*Figure 5B*](#fig5){ref-type="fig"}*), but at 37°C there is a more than 30% increase in hydrolysis activity (*[*Figure 6--figure supplement 1C*](#fig6s1){ref-type="fig"}*). The authors should try to explain those temperature-dependent differences in behavior*.

This is an interesting point, and one that we cannot readily explain. It is possible that the W221A mutant is not entirely defective in substrate recognition and engagement, and that the mutation's effect varies somewhat at different temperatures. Even at 37°C, the mutant has much higher basal ATPase activity than wild-type TRIP13. Also, in our MAD2 conversion assays---performed at 37°C---showed no activity for TRIP13^W221A^ ([Figure 7D](#fig7){ref-type="fig"}, bottom panel), indicating that even if this mutant is somewhat stimulated by p31(comet):MAD2 at 37°C, it is still unable to mediate C-MAD2 to O-MAD2 conversion.

*10) In the Discussion section the authors discuss TRIP13\'s mode of substrate recognition, which seems to include an initial interaction of the p31 adaptor with the TRIP13 N-terminal domain, before the MAD2 substrate binds in the central pore. The authors state:* "*its mode of substrate recognition, which parallels not ClpX but a family of 'classic remodelers' including NSF, p97, and Pex1.*" *I am sure the Corbett group is aware that many ClpX substrates with N-terminal degradation signals initially interact with the ClpX N-terminal domain before they are transferred to the central pore, and ClpX adaptors also bind to the N-terminal domain for substrate delivery to the central pore. The overall process of substrate delivery to TRIP13 thus appears to strongly parallel the mechanisms of ClpX, even though there are differences in the architecture of the N-terminal domains. The authors should clarify or correct their statement to prevent confusion*.

We thank the reviewer for pointing this out, and have altered the sentence in question to read: "...its mode of substrate recognition, which is mediated by an N-terminal domain related to a family of 'classic remodelers' including NSF, p97, and PEX1."

*11) There is a mistake in a figure reference in the last paragraph of the subsection headed "p31(comet) functions as an adapter between MAD2 and TRIP13*"*. The sentence* "*Semi-quantitative analysis of Coomassie-stained gels, and light-scattering based molecular-weight measurements on this peak, revealed that for each TRIP13E235Q hexamer, about 1 copy of each protein was shifted into the TRIP13 peak (*[*Figure 4D*](#fig4){ref-type="fig"}*, Figure 4--figure supplement 4)...*" *should reference* [*Figure 4E*](#fig4){ref-type="fig"}*, not 4D*.

Because of the overhaul of figure format and numbering, this figure panel has been changed (now [Figure 5E](#fig5){ref-type="fig"}), but we have made sure that the text now refers to the correct figure panel.

[^1]: *R*~sym~ = ∑∑~j~\|*I*~j~ − 〈*I*〉\|/∑*I*~j~, where *I*~j~ is the intensity measurement for reflection j and 〈*I*〉 is the mean intensity for multiply recorded reflections.

[^2]: *R*~meas~ = ∑~h~ \[√(*n*/(*n* − 1)) ∑~j~ \[*I*~hj~ − 〈*I*~h~〉\]/∑~hj~ 〈*I*~h~〉 where *I*~hj~ is a single intensity measurement for reflection h, 〈*I*~h~〉 is the average intensity measurement for multiply recorded reflections, and *n* is the number of observations of reflection h.

[^3]: CC~1/2~ is the Pearson correlation coefficient between the average measured intensities of two randomly-assigned half-sets of the measurements of each unique reflection ([@bib26]).

[^4]: High-resolution native data were anisotropically scaled and elliptical data cutoffs were applied according to directional intensity and CC~1/2~ data (see 'Materials and methods' and [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"} for details on data anisotropy and resolution cutoffs).

[^5]: *R*~work,\ free~ = ∑\|\|F~obs~\| − \|F~calc~\|\|/\|F~obs~\|, where the working and free *R*-factors are calculated using the working and free reflection sets, respectively.

[^6]: Coordinates and structure factors have been deposited in the RCSB Protein Data Bank ([www.pdb.org](http://www.pdb.org)).
